3-Protocols, CPR Guidelines, & Appendix
3-Protocols, CPR Guidelines, & Appendix
Protocols
CPR Clinical Guidelines
Anesthesia and
Analgesia
for the Veterinary Practitioner: Canine and Feline
Appendix
©Banfield 2022.04
Asa status
Emergency drug dosing
Status ASA classification Examples
I Healthy pet, no disease Elective OVH or castration Drug Low dose High dose
■ History Amiodarone
5 mg/kg N/A
■ Clinical Pathology Data 50 mg/mL
■ Physical Exam Reversal agents
CLINICAL Equal to amount of
ESSENTIAL dexmedetomidine
Atipamezole
I -II 100 mcg/kg administered if dose
The attending 5 mg/mL
■ There is little to no increase in risk was higher than 10
veterinarian mcg/kg
chooses protocols Butorphanol
0.05 mg/kg 0.1 mg/kg
and determines 10 mg/mL
specific drug Flumazenil Repeat every hour if
III - V 0.01 mg/kg
■ Discuss increased risk with the client dosages 0.1 mg/mL needed
■ Maximize preanesthetic
Naloxone
medical management 0.04 mg/kg N/A
0.4 mg/mL
■ Cancel or refer procedure as
clinically indicated
State regulations
■ At all times, every medical team must comply with individual state
practice acts.
■ It is each doctor’s responsibility to know and understand the
requirements of his/her specific state, as well as Banfield policies
and procedures.
■ The doctor must ensure compliance with state regulations regarding:
● Handling and administration of controlled substances
● Intubation of pets
● Anesthetic monitoring
● Drug administration documentation
● Which hospital associates can legally perform dental prophylaxis and
all other medical procedures
● Off-label usage of medications
This publication may contain information that is not within the current FDA-
approved labeling for several products for companion animals.
Contributing authors
Introduction 2
Protocols 4
Abdominal/hepatic 4
Brachycephalic 12
Caesarean section 21
Cardiac 29
Dental prophylaxis 39
Diabetic (stable) 47
Emergency 55
Geriatric 63
Hands-free radiology 73
Obese (stable) 79
Orthopedic 87
Pediatric 95
Renal/post-renal 103
Sighthounds 121
Soft tissue (elective) 127
Stressed/fractious 134
Addendum 144
CPR clinical guidelines
Appendix
Abbreviations
DKT dexmedetomidine,
ketamine, torbutrol
ECG electrocardiogram
EtCO2 end-tidal carbon dioxide
1 Book 3
Protocols
Introduction
Protocols have been developed from an evaluation of the current
literature and the consensus of board-certified veterinary specialists
(anesthesiology and internal medicine). Protocols are never meant to
be followed blindly and the anesthesia team remains responsible for
making decisions in the best interest of the patient.
Examples:
■ If a protocol calls for cefazolin but the patient is allergic to
cephalosporins, administer a different antibiotic
■ If a protocol utilizes acepromazine, but the patient is undergoing
medical therapy for a portosystemic shunt, administer a
different premedication
Protocols 2
Protocols
3 Book 3
Abdominal/Hepatic
Abdominal
Examples
Hepatic dysfunction Intervention
Hypoglycemia Dextrose CRI
Hypoalbuminemia Colloid support
Coagulopathy Vitamin K or transfusion therapy
Protocols 4
Abdominal/Hepatic
Premedication
Drug Dose Route
Canine 0.05–0.2 mg/kg
Hydromorphone
Feline 0.05–0.1 mg/kg IM, SC
Midazolam 0.1–0.3 mg/kg
OR
Methadone 0.25 mg/kg
IV
+/- Midazolam 0.05 mg/kg
OR
if there is a history of vomiting:
Midazolam 0.1–0.3 mg/kg IM, SC
Buprenorphine 0.01–0.02 mg/kg IM, IV
5 Book 3
Abdominal/Hepatic
Transition phase
Post-induction inhalant rates
Protocols 6
Abdominal/Hepatic
Anesthetic maintenance
Drugs Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
■ Prevent/treat hypothermia associated with a large, open abdomen
(see Induction, Monitoring and Recovery chapter for details)
■ Be prepared to adjust oxygen flow rates in response to patient
clinical parameters
■ Amount of sevoflurane will vary with patient health, analgesic
therapy and local blocks used
■ If 4% or more sevoflurane is required:
● Check the anesthesia system for leaks
● Ensure appropriate analgesia
● Consider:
□ Inadequate premedication
□ Improper endotracheal intubation, etc.
○ See Equipment chapter for more details
7 Book 3
Abdominal/Hepatic
Anticholinergics
Protocols 8
Abdominal/Hepatic
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
■ If recovery is slow, recheck BG concentrations
9 Book 3
Abdominal/Hepatic
Protocols 10
Abdominal/Hepatic
Analgesia to go home
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
11 Book 3
Brachycephalic
Brachycephalic
Anticipated problems
■ Preoperative airway obstruction after premedication
■ Difficulty visualizing the larynx during intubation
Protocols 12
Brachycephalic
Examples
ANY pet with a shortened snout
Boston Terrier Boxers
Bulldogs Himalayan
Lhasa Apso Persian
Pugs Shih Tzu
OR
■ Consider giving the first dose the night before along with another
dose the morning of the procedure
■ Trazodone can cause paradoxical excitement. Trial doses
are recommended.
13 Book 3
Brachycephalic
Premedication
Drug Dose Route
Butorphanol 0.2–0.4 mg/kg IM
Midazolam 0.1–0.3 mg/kg IM
■ For procedures that need analgesia, avoid opioids that induce vomiting
in the premedication. Supplement with another opioid once the patient
is intubated and asleep (45-60minutes after the butorphanol).
■ Consider pre-operative thoracic radiographs to evaluate the lungs and
heart. These patients can be difficult to auscultate and are prone to
aspiration pneumonia. Identifying underlying conditions early increases
anesthetic safety.
■ Never muzzle or restrict the airway in any brachycephalic patient and
use minimum physical restraint necessary
■ Anxiolytics may be helpful but should not be used in place of safe
patient handling practices
● Cautious use of acepromazine at low-dose (0.01 mg/kg) may be
considered if patients are significantly anxious
● Patient analgesic needs should be considered
■ Use maropitant to reduce the risk of vomiting.
■ Other perianesthetic protocols to decrease post-operative GI complications:
● Famotidine 1mg/kg IV or SQ
● Metoclopramide 0.5mg/kg SQ
● Omeprazole 1mg/kg PO
● If history of regurgitation: 1 week of PPI and metoclopramide
■ Pre-oxygenation for at least 3-5 minutes is very important for
these patients if they will tolerate it, but stress should be kept to
a minimum.
■ Once premedicated, these patients should be kept under
observation at ALL times
Protocols 14
Brachycephalic
Transition phase
Post-induction inhalant rates
15 Book 3
Brachycephalic
Anesthetic maintenance
Drugs Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
■ Once intubated these patients usually do well due to upper airway
bypass (until extubation)
■ Be prepared to adjust oxygen flow rates in response to patient
clinical parameters
■ Amount of sevoflurane will vary with patient health, analgesic
therapy and local blocks used
■ If 4% or more sevoflurane is required:
● Check the anesthesia system for leaks
● Ensure appropriate analgesia
● Consider:
□ Inadequate premedication
□ Improper endotracheal intubation, etc.
○ See Equipment chapter for more details
■ Inspect the pharynx frequently for reflux
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 16
Brachycephalic
17 Book 3
Brachycephalic
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
Protocols 18
Brachycephalic
19 Book 3
Brachycephalic
Analgesia to go home
Drug Dosage Route
NSAID
PO once daily or divided into
Carprofen Canine 4 mg/kg
2 doses for 3–5 days
Meloxicam Canine 0.1 mg/kg PO, every 24 hours
PO once daily for a
maximum of 3 total doses
Robenacoxib Feline 1 mg/kg over 3 days.
Do not exceed
1 dose per day.
OPIOID
Canine 5 mg/kg
Tramadol* PO, every 6 hours
Feline 2–4 mg/kg
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
*Oral tramadol has not been shown to be effective postoperatively in dogs.
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 20
Caesarean section
Caesarean section
What is different about this patient?
Patients that require a caesarean section (C-section) may be
hemodynamically stable and have a relatively unremarkable
physical examination. Conversely, patients may be critically ill with
complications of pregnancy/delivery and may require significant
medical stabilization before proceeding to general anesthesia.
Respiratory compromise may occur when patients with a large,
gravid uterus are placed in dorsal recumbency. It is recommended,
when possible, to perform abdominal imaging preoperatively to help
determine treatment plan and management. This may also allow a
determination of fetal number and viability.
Large volumes of fluid and/or blood may potentially be lost with a
C-section and replacement needs should be anticipated. Additionally,
the use of certain drugs should be avoided in a pregnant patient:
■ Acepromazine
■ Ketamine
■ Benzodiazepines (midazolam, zolazepam)
■ Alpha-2 agonists (dexmedetomidine)
Additional considerations:
■ It is important to minimize fetal exposure to inhalant anesthetic
agents. However, the surgeon should wait 10 - 15 minutes post-
induction to remove fetuses from the uterus, to allow for metabolism
and redistribution of injectable agents.
■ Preloading with a fluid bolus may help avoid hypotension, which
occurs when puppies/kittens are delivered. Begin fluid bolus as
indicated per patient when abdomen is incised.
■ Prevent/treat hypothermia associated with a large, open abdomen
(see Induction, Monitoring and Recovery chapter for details).
21 Book 3
Caesarean section
Premedication
Drug Dose Route
Butorphanol 0.2–0.4 mg/kg IM, SC
OR
Methadone 0.2 mg/kg IM, IV
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 22
Caesarean section
Transition phase
Post-induction inhalant rates
Inhalant Rates Miscellaneous
50–100 mL/kg/minute
(rebreathing) For first 15 minutes
Oxygen
150–300 mL/kg/minute after induction
(NRB)
Large dogs may
Sevoflurane 3% for 3 minutes
need higher rates
■ Be prepared to perform manual ventilation
■ Monitor anesthetic depth and oxygenation closely
23 Book 3
Caesarean section
Anesthetic maintenance
Drugs Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 24
Caesarean section
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
25 Book 3
Caesarean section
Local Block
OR
Reduced dose of lidocaine
Line blocks for
OR
abdominal incision
bupivacaine (see below)
Antibiotics
If medically indicated, See Medical Quality
cefazolin is recommended Standards chapter
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 26
Caesarean section
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
Resuscitation of pups/kits:
■ Provide warmth and gentle stimulation
■ Provide supplemental oxygen
■ If spontaneous respiration is not occurring:
● Consider intubation, depending on size
● Administer oxygen
● If dam was given opioid prior to delivery, apply one drop of
naloxone sublingually to each pup or kit
● DO NOT administer doxapram
● DO NOT swing/sling pups or kits
● Gentle suction of nose, mouth and airways may be performed
■ Place pups/kits with dam as soon as complete recovery is attained
● Ensure patient is fully recovered before leaving pups/kits unattended
27 Book 3
Caesarean section
Analgesia to go home
Drug Dosage Route
Canine 5 mg/kg PO, every
Tramadol*
Feline 2–4 mg/kg 6 hours
OR
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
*Oral tramadol has not been shown to be effective postoperatively in dogs.
Protocols 28
Cardiac
Cardiac
What is different about this patient?
Patients with cardiac disease are at an increased risk for clinical
decompensation, fluid overload and potentially cardiac arrhythmias
with anesthesia. Remember that the presence or absence of a murmur
does not equate to clinical cardiac disease.
Patients with known or suspected congenital cardiac disease (e.g.,
patent ductus arteriosus, ventricular septal defect, pulmonic stenosis)
that has not been corrected should not undergo general anesthesia
due to high potential risks. If anesthesia cannot be avoided and
referral is not an option, consider the Cardiac protocol.
Patients with known but stable cardiac disease should be thoroughly
assessed prior to anesthesia (e.g., thoracic radiographs, blood
pressure, ECG, minimum data base) to ensure disease is clinically
stable. See the 2009 American College of Veterinary Internal Medicine
(ACVIM) Consensus Statement on Chronic Valvular Disease for a
discussion on the classification of heart disease and heart failure for
details.
Additional considerations:
■ Blood pressure may be affected by comorbid conditions (e.g., renal
or endocrine disease) so ensure complete clinical picture is obtained
prior to anesthesia
■ If patients have evidence of clinical decompensation, stabilize
medically and reschedule anesthesia. If anesthesia cannot be
avoided and referral is not an option, consider the Cardiac protocol.
■ Complete cardiac work-ups are recommended for all patients with
cardiac disease prior to anesthesia:
● ECG
● Echocardiogram
● BP
■ Minimum Data Base (MDB) for these patients should include 2 view
thoracic radiographs, labwork and urine prior to the procedure
29 Book 3
Cardiac
Canine examples
Breeds with known risk of Doberman Pinscher
cardiac arrhythmias ECG Boxer
Breeds with increased
incidence
King Charles Cavalier Spaniel
of mitral valve disease
Thoracic radiographs
Feline considerations
Potential presence of subclinical See Physiology chapter
cardiac disease (HCM) for details
Premedication
Drug Dose Route
Midazolam 0.1–0.3 mg/kg IM, SC
Butorphanol 0.2– 0.4 mg/kg IM, SC
OR
Midazolam 0.1–0.2 mg/kg IM, SC
Canine 0.05–0.2 mg/kg IM
Hydromorphone
Feline 0.05–0.1 mg/kg SC
■ Consider if additional analgesic therapy is warranted based on:
Protocols 30
Cardiac
31 Book 3
Cardiac
Transition phase
Post-induction inhalant rates
Inhalant Rates Miscellaneous
50–100 mL/kg/minute
(rebreathing) For first 15 minutes
Oxygen
150–300 mL/kg/minute after induction
(NRB)
Large dogs may
Sevoflurane 3% for 3 minutes
need higher rates
■ Monitor anesthetic depth and oxygenation closely
Protocols 32
Cardiac
Anesthetic maintenance
Inhalant Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
33 Book 3
Cardiac
■ Fluid rates for patients with cardiac disease are decreased due to
concerns of possible fluid overload
● Monitor patient cardiovascular parameters closely and change
fluid rate as indicated
■ Intraoperative analgesia as indicated by patient clinical status
● See The Individualized Anesthesia and Analgesia Plan chapter
for details
■ Anticholinergics as clinically indicated for bradycardia accompanied
by hypotension
● Use with caution in patients with cardiac disease
● If anticholinergics are administered, continuous ECG monitoring
for cardiac arrhythmias is critical
Protocols 34
Cardiac
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
35 Book 3
Cardiac
Protocols 36
Cardiac
Analgesia to go home
Drug Dosage Route
NSAID
PO once daily or
Carprofen Canine 4 mg/kg divided into 2 doses
for 3–5 days
Meloxicam Canine 0.1 mg/kg PO, every 24 hours
PO once daily for a
maximum of 3 total
Robenacoxib Feline 1 mg/kg doses over 3 days.
Do not exceed 1
dose per day.
OPIOID
Canine 5 mg/kg
Tramadol* PO, every 6 hours
Feline 2–4 mg/kg
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
*Oral tramadol has not been shown to be effective postoperatively in dogs.
37 Book 3
Cardiac
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 38
Dental prophylaxis
Dental prophylaxis
What is different about this patient?
This same protocol for anesthesia and recovery can be used for
healthy, elective soft tissue surgery. However, it is important to
evaluate the patient for dental prophylaxis very carefully; patients with
significant tooth disease may be geriatric or have concurrent disease,
which must be taken into account (see other protocols depending
on the nature of the concurrent disease). Use the dental prophylaxis
protocol in those healthy pets when no concurrent diseases or patient-
specific factors impacting anesthesia are present. Healthy geriatric
patients undergoing routine dental prophylaxis should be anesthetized
using the Geriatric protocol.
Dental prophylaxis is considered a non-sterile procedure. It has
been shown that bacteremia occurs with routine dental prophylaxis,
independent of the severity of dental disease. Performing sterile
procedures under the same anesthesia as a dental prophylaxis is
not recommended due to concerns of contamination.
Unique risks to the patient undergoing a dental prophylaxis include:
■ Hypothermia
● Length of time of procedure
● Potential for fur to become soaked with flushing solution
■ Aspiration
● Potentially large volume of oral flushing solutions
● Incorrect or incomplete ET cuff inflation
■ Thermal burns
● Potentially saturated fur and prolonged recumbency on
warming devices
● Be especially cautious in older patients/patients with thin
body condition
39 Book 3
Dental prophylaxis
Premedication
Drug Dose Route
Midazolam 0.1–0.3 mg/kg IM, SC
Butorphanol 0.2–0.4 mg/kg IM, SC
OR
Acepromazine 0.02–0.05 mg/kg IM, SC
Butorphanol 0.2–0.4 mg/kg IM, SC
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 40
Dental prophylaxis
Transition phase
Post-induction inhalant rates
Inhalant Rates Miscellaneous
50–100 mL/kg/minute
(rebreathing) For first 15 minutes
Oxygen
150–300 mL/kg/minute after induction
(NRB)
Large dogs may
Sevoflurane 3% for 3 minutes
need higher rates
■ Monitor anesthetic depth and oxygenation closely
41 Book 3
Dental prophylaxis
Anesthetic maintenance
Drugs Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
■ High volumes of water may be used to rinse and flush the oral cavity
during dental prophylaxis
● Ensure patient fur does not become saturated with water
● This may predispose to hypothermia and potentially thermal burns
(especially if thin body condition)
□ Keep patients as dry as possible
■ Be prepared to adjust oxygen flow rates in response to patient
clinical parameters
■ Amount of sevoflurane will vary with patient health, analgesic
therapy and local blocks used
■ If 4% or more sevoflurane is required:
● Check the anesthesia system for leaks
● Ensure appropriate analgesia
● Consider:
□ Inadequate premedication
□ Improper endotracheal intubation, etc.
○ See Equipment chapter for more details
Protocols 42
Dental prophylaxis
43 Book 3
Dental prophylaxis
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 44
Dental prophylaxis
45 Book 3
Dental prophylaxis
Analgesia to go home
Drug Dosage Route
NSAID
PO once daily or
Carprofen Canine 4 mg/kg divided into 2 doses
for 3–5 days
Meloxicam Canine 0.1 mg/kg PO, every 24 hours
PO once daily for a
maximum of 3 total
Robenacoxib Feline 1 mg/kg doses over 3 days.
Do not exceed 1
dose per day.
OPIOID
Canine 5 mg/kg
Tramadol* PO, every 6 hours
Feline 2–4 mg/kg
0.01–0.02 Transmucosal,
Buprenorphine Feline
mg/kg every 8 hours
*Oral tramadol has not been shown to be effective postoperatively in dogs.
Protocols 46
Diabetic (stable)
Diabetic (stable)
47 Book 3
Diabetic (stable)
■ Consider giving the first dose the night before along with another
dose the morning of the procedure
■ Trazodone can cause paradoxical excitement. Trial doses
are recommended.
Premedication
Drug Dose Route
Acepromazine 0.02–0.05 mg/kg IM, SC
Butorphanol 0.2–0.4 mg/kg IM, SC
OR
Midazolam 0.1–0.3 mg/kg IM, SC
Butorphanol 0.2–0.4 mg/kg IM, SC
Protocols 48
Diabetic (stable)
49 Book 3
Diabetic (stable)
Transition phase
Post-induction inhalant rates
Anesthetic maintenance
Drugs Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
Protocols 50
Diabetic (stable)
Intravenous
Rate Miscellaneous
Fluids
Canine 5 mL/kg/hour Higher fluid rates
may be needed
if patient is not
Crystalloids
Feline 3 mL/kg/hour adequately
hydrated when
anesthesia begins
Anticholinergics
Drug Dose Route
Atropine 0.02–0.04 mg/kg IV
Glycopyrrolate 0.005–0.01 mg/kg IV
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
51 Book 3
Diabetic (stable)
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on
SpO2 95–100%
room air
Sternal recumbency
Pain controlled Pain score <2
■ Patient should be offered a small amount of food as early as possible
when fully awake and able to eat without risk of aspiration
Protocols 52
Diabetic (stable)
53 Book 3
Diabetic (stable)
Analgesia to go home
Drug Dosage Route
NSAID
PO once daily or
Carprofen Canine 4 mg/kg divided into 2 doses
for 3–5 days
Meloxicam Canine 0.1 mg/kg PO, every 24 hours
PO once daily for a
maximum of 3 total
Robenacoxib Feline 1 mg/kg doses over 3 days.
Do not exceed 1 dose
per day.
OPIOID
Canine 5 mg/kg
Tramadol* PO, every 6 hours
Feline 2–4 mg/kg
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
* Oral tramadol has not been shown to be effective postoperatively in dogs.
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 54
Emergency
Emergency
What is different about this patient?
True emergencies are surgical cases that require immediate
anesthesia (within 15 minutes) to save the patient’s life.
These situations are rare and thus this protocol should be
infrequently used
Examples
Airway obstruction, Life-threatening
bilateral pneumothorax acute hemorrhage
55 Book 3
Emergency
Premedication
Drug Dose Route
Midazolam 0.1–0.3 mg/kg IM, SC
Butorphanol 0.2–0.4 mg/kg IM, SC
■ Consider if additional analgesic therapy is warranted, based on:
● Signalment ● Anesthetic indication
● Physical examination ● Surgical intervention planned
■ If analgesic therapy is warranted, replace butorphanol in
the premedication with another opioid listed in Additional
Analgesic Therapy
Protocols 56
Emergency
Transition phase
Post-induction inhalant rates
57 Book 3
Emergency
Anesthetic maintenance
Drugs Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 58
Emergency
59 Book 3
Emergency
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
Protocols 60
Emergency
61 Book 3
Emergency
Analgesia to go home
Drug Dosage Route
Canine 5 mg/kg PO, every
Tramadol*
Feline 2–4 mg/kg 6 hours
OR
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
*Oral tramadol has not been shown to be effective postoperatively in dogs.
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 62
Geriatric
Geriatric
What is different about this patient?
Geriatric patients are usually considered to be those that have
reached 75–80 percent of breed-specific lifespan. An age of 8 years
for dogs and 12 years for cats may be a good estimate.
It is important to review the medical history of these patients closely
as they may be receiving medications for concurrent diseases or
analgesic medication (including NSAIDs) for known or presumptive
arthritis. These patients should be scrutinized for concurrent diseases
with careful physical examination, clinical pathology evaluation and
additional testing if medically indicated.
■ Use the Geriatric protocol in those pets where no concurrent
disease conditions are identified or suspected.
● Geriatric patients undergoing a routine dental prophylaxis should
be anesthetized using the Geriatric protocol.
■ If concurrent disease is identified in a geriatric patient, then the
protocol specific to that disease should be utilized.
● The most common conditions include cardiac, renal and hepatic
disease (see specific protocols for details).
■ Thoracic radiographs are recommended within 6 months prior to
any anesthesia
63 Book 3
Geriatric
Complications to consider:
■ Increased anxiety
■ Arthritis - patients may need additional padding during the
procedure, low-stress handling techniques and more support when
moving/carrying
■ Decreased dose adjustments
■ Use of the saphenous vein for IV catheter to decrease stress and handling
Examples
Reasonable Canine: > 8 years
(adjust for size/breed) No concurrent
estimates for
disease
geriatric ages Feline: >12 years
Protocols 64
Geriatric
Premedication
Drug Dose Route
Low dose
0.01 mg/kg IM
Acepromazine
Butorphanol 0.2 mg/kg IM
OR
Midazolam 0.1 mg/kg IM
Butorphanol 0.2–0.4 mg/kg IM
OR
IM (volume limits to
Alfaxalone 2 mg/kg
small patients only)
Butorphanol 0.2-0.4 mg/kg IM
OR
65 Book 3
Geriatric
Protocols 66
Geriatric
Transition phase
Post-induction inhalant rates
Inhalant Rates Miscellaneous
50–100 mL/kg/minute
(rebreathing) For first 15 minutes
Oxygen
150–300 mL/kg/minute after induction
(NRB)
Large dogs may
Sevoflurane 3% for 3 minutes
need higher rates
■ Monitor anesthetic depth and oxygenation closely
Anesthetic maintenance
Inhalant Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
67 Book 3
Geriatric
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 68
Geriatric
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
69 Book 3
Geriatric
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
Protocols 70
Geriatric
71 Book 3
Geriatric
Analgesia to go home
Drug Dosage Route
NSAID
PO once daily or
Carprofen Canine 4 mg/kg divided into 2 doses
for 3–5 days
Meloxicam Canine 0.1 mg/kg PO, every 24 hours
PO once daily for a
maximum of 3 total
Robenacoxib Feline 1 mg/kg doses over 3 days.
Do not exceed 1
dose per day.
OPIOID
Canine 5 mg/kg
Tramadol* PO, every 6 hours
Feline 2–4 mg/kg
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
*Oral tramadol has not been shown to be effective postoperatively in dogs.
Protocols 72
Geriatric
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
73 Book 3
Hands-free radiology
Hands-free radiology
Examples
Coxofemoral joint
Orthopedic injury Neoplasia staging
assessment
Protocols 74
Hands-free radiology
■ Consider giving the first dose the night before along with another
dose the morning of the procedure
■ Trazodone can cause paradoxical excitement. Trial doses
are recommended.
Premedication
Drug Dose Route
Midazolam 0.1–0.3 mg/kg
IM, SC
Butorphanol 0.2–0.4 mg/kg
OR
Acepromazine 0.02–0.05 mg/kg
IM, SC
Butorphanol 0.2–0.4 mg/kg
OR
Dexmedetomidine 2–5 mcg/kg
Canine IM
Butorphanol 0.2–0.4 mg/kg
OR
DKT mixture.
See Appendix
Feline 0.035 mL/kg IM
chapter for mixing
instructions.
75 Book 3
Hands-free radiology
Protocols 76
Hands-free radiology
Maintenance/monitoring
Support
77 Book 3
Hands-free radiology
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
■ As medically indicated
Protocols 78
Hands-free radiology
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
79 Book 3
Obese (stable)
Obese (stable)
What is different about this patient?
Obese patients are those with a body weight 20 – 30 percent or more above
ideal. For optimal patient safety in elective procedures, postpone general
anesthesia and institute a directed weight loss program. General anesthesia
should be then pursued when ideal body weight has been reached.
If there is a need to proceed to anesthesia with an obese patient, drug
doses and IV fluid rates should be calculated on lean body weight. Body
fat stores do not add to the metabolic fate of medications. This involves
a degree of estimating as to what lean body weight should be. Previous
medical history with body weight and body condition score may be helpful
in determining accurate estimates. If in doubt, underestimate what the
patient’s weight should be — additional drugs can always be given if
administered doses appear ineffective.
Additional considerations:
■ Intramuscular and IV injections should be considered. Larger amounts
of SC fat lead to variable drug absorption with SC injections. Lumbar
injections are likely to only reach the SC space in obese animals.
■ Estimated lean body weight should be used to determine endotracheal
tube size, size of the rebreathing circuit and bag, tidal volume to be
delivered and may influence the size of IV catheter chosen for the patient.
● Premedication, induction agents, maintenance and analgesic
medications should have doses calculated on estimated lean
body weight.
■ Obesity will have a major impact on the patient’s ability to ventilate
adequately, especially when placed in dorsal recumbency. Monitor
oxygenation closely and be ready to assist ventilation.
■ Complications to consider:
● Passive gastric reflux/regurgitation
● Hypoxemia
● Hyperthermia
● Upper airway obstruction when not intubated
● Difficulty identifying landmarks and placing IV catheters
● Hypoventilation especially when the head is tilted lower
Protocols 80
Obese (stable)
Premedication
Drug Dose Route
Midazolam 0.1–0.3 mg/kg
IM, SC
Butorphanol 0.2–0.4 mg/kg
OR
Acepromazine 0.02–0.05 mg/kg
IM, SC
Butorphanol 0.2–0.4 mg/kg
81 Book 3
Obese (stable)
Transition phase
Post-induction inhalant rates
Protocols 82
Obese (stable)
Anesthetic maintenance
Inhalant Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
■ Remember that obesity will have a major impact on the patient’s ability
to ventilate adequately, especially when placed in dorsal recumbency
● Monitor oxygenation closely and be ready to assist ventilation
■ Obese patients may have ineffective cooling mechanisms and
may be prone to hyperthermia
● Monitor temperatures closely
■ Be prepared to adjust oxygen flow rates in response to patient
clinical parameters
■ Amount of sevoflurane will vary with patient health, analgesic
therapy and local blocks used
■ If 4% or more sevoflurane is required:
● Check the anesthesia system for leaks
● Ensure appropriate analgesia
● Consider:
□ Inadequate premedication
□ Improper endotracheal intubation, etc.
○ See Equipment chapter for more details
83 Book 3
Obese (stable)
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 84
Obese (stable)
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
■ If drugs have been carefully administered in minimal dosages,
recovery of the obese patient should be fairly rapid
■ Obese patients may not ventilate well; place them in sternal
recumbency and give oxygen by facemask until they are able
to maintain saturation (SpO2 above 95%) by themselves and
temperature is above 100 ° F
■ Extremely obese patients might have difficulty righting themselves if
they fall into lateral recumbency
● Ensure complete visual observation until patient is mobile
85 Book 3
Obese (stable)
Protocols 86
Obese (stable)
Analgesia to go home
Drug Dosage Route
NSAID
PO once daily or
Carprofen Canine 4 mg/kg divided into 2 doses
for 3–5 days
Meloxicam Canine 0.1 mg/kg PO, every 24 hours
PO once daily for a
maximum of 3 total
Robenacoxib Feline 1 mg/kg doses over 3 days.
Do not exceed 1
dose per day.
OPIOID
Canine 5 mg/kg
Tramadol* PO, every 6 hours
Feline 2–4 mg/kg
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
*Oral tramadol has not been shown to be effective postoperatively in dogs
■ NSAID and/or opioid as appropriate for health status
■ Dispense the same NSAID that was utilized postoperatively
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
87 Book 3
Orthopedic
Orthopedic
Protocols 88
Orthopedic
Premedication
Drug Dose Route
Acepromazine 0.02–0.05 mg/kg
Canine 0.05–0.2 mg/kg IM, SC
Hydromorphone
Feline 0.05–0.1 mg/kg
OR
Midazolam 0.1–0.3 mg/kg
Canine 0.05–0.2 mg/kg IM, SC
Hydromorphone
Feline 0.05–0.1 mg/kg
89 Book 3
Orthopedic
Transition phase
Post-induction inhalant rates
Protocols 90
Orthopedic
Anesthetic maintenance
Anesthetic Rates
maintenance
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
91 Book 3
Orthopedic
Intravenous
Rate Miscellaneous
Fluids
Higher fluid rates
Canine 5 mL/kg/hour may be needed
if patient is not
Crystalloids
adequately
Feline 3 mL/kg/hour hydrated when
anesthesia begins
Anticholinergics
Drug Dose Route
Atropine 0.02–0.04 mg/kg IV
Glycopyrrolate 0.005–0.01 mg/kg IV
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 92
Orthopedic
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
93 Book 3
Orthopedic
Protocols 94
Orthopedic
Analgesia to Go Home
Drug Dosage Route
NSAID
PO once daily or
Carprofen Canine 4 mg/kg divided into 2 doses
for 3–5 days
Meloxicam Canine 0.1 mg/kg PO, every 24 hours
PO once daily for a
maximum of 3 total
Robenacoxib Feline 1 mg/kg doses over 3 days.
Do not exceed
1 dose per day.
OPIOID
Canine 5 mg/kg
Tramadol PO, every 6 hours
Feline 2–4 mg/kg
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
Fentanyl patch Follow dosing chart Transdermal
95 Book 3
Pediatric
Protocols 96
Pediatric
Normal puppy/kitten
Age Physical Parameter
value
<2 weeks Temperature 96–97° F
Total white blood Decreased compared
3 weeks
cell count to adults
Decreased compared
<4 weeks Albumin*
to adults
4 weeks Temperature 100° F
<6 weeks Urine color Colorless
<7 weeks Packed cell volume 27%
8 weeks Albumin Normal adult value
*Puppies and kittens may have greater sensitivity to highly protein-bound medications
97 Book 3
Pediatric
Premedication
Drug Dose Route
Midazolam 0.1–0.3 mg/kg
IM
Butorphanol 0.2–0.4 mg/kg
PLUS
Glycopyrrolate 0.01 mg/kg IM
OR
May be used in place
Atropine 0.02–0.04 mg/kg of glycopyrrolate in
case of back orders
■ Remember that cardiac output depends primarily on cardiac
rate in pediatric patients because of decreased stroke volume
■ Consider preemptive warming post premedication due to increased
risk for hypothermia
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 98
Pediatric
Transition phase
Post-induction inhalant rates
Inhalant Rates Miscellaneous
50–100 mL/kg/minute
(rebreathing) For first 15 minutes
Oxygen
150–300 mL/kg/minute after induction
(NRB)
Large puppies may
Sevoflurane 3% for 3 minutes
need higher rates
■ Monitor anesthetic depth and oxygenation closely
99 Book 3
Pediatric
Anesthetic maintenance
Inhalant Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
Protocols 100
Pediatric
101 Book 3
Pediatric
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
Protocols 102
Pediatric
Analgesia to go home
Drug Dosage Route
NSAID
PO once daily
or divided into
Carprofen Puppies 4 mg/kg
2 doses for
3 - 5 days
OPIOID
Transmucosal,
Buprenorphine Kittens 0.01–0.02 mg/kg
every 8 hours
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
103 Book 3
Renal/post-renal
Renal/post-renal
(urinary/urethral obstruction)
Examples
Urethral obstruction Chronic renal disease
Acute renal injury Presence of ureteroliths
Protocols 104
Renal/post-renal
Premedication
Drug Dose Route
Midazolam 0.1–0.3 mg/kg IM, SC
Butorphanol 0.2–0.4 mg/kg IM, SC
OR (if chemical restraint required for obstructed cats)
Alfaxalone 2 mg/kg IM (wait 10 minutes
Butorphanol 0.2 mg/kg before attempting
Atropine 0.02 mg/kg IV catheter)
105 Book 3
Renal/post-renal
Transition phase
Post-induction inhalant rates
Protocols 106
Renal/post-renal
Anesthetic maintenance
Drugs Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
107 Book 3
Renal/post-renal
■ Monitor fluid input and urine output closely and evaluate frequently
for signs of over hydration
● Consider measuring patient ins and outs to best individualize
fluid therapy
■ Additional support to assist and maintain renal perfusion with
colloids and dobutamine CRIs may be indicated
■ Intraoperative analgesia as indicated by patient clinical status
● See The Individualized Anesthesia and Analgesia Plan chapter for details
Protocols 108
Renal/post-renal
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
109 Book 3
Renal/post-renal
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 110
Renal/post-renal
111 Book 3
Renal/post-renal
Analgesia to go home
Drug Dosage Route
OPIOID
Canine 5 mg/kg
Tramadol* PO, every 6 hours
Feline 2–4 mg/kg
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 112
Respiratory compromise
Respiratory compromise
What is different about this patient?
Patients with respiratory compromise may decompensate rapidly and
quickly become critically hypoxemic. Stabilize as much as possible
prior to any procedure and continually monitor patient oxygenation.
Control and manage the airway not only under anesthesia but
throughout the recovery phase.
Additional considerations:
■ Anesthetic and analgesic agents tend to depress respiration and
administration of these agents could result in worsening of patient
status and potentially be fatal.
■ Be aware of risks and monitor closely — always be ready to
intervene with assisted ventilation.
● See Induction, Monitoring and Recovery chapter for details on
hypoventilation/hypoxemia.
Examples
Chronic Conditions Acute Respiratory Distress
Collapsing trachea Pleural effusion
Asthma Diaphragmatic hernia
113 Book 3
Respiratory compromise
Premedication
Drug Dose Route
Midazolam 0.1–0.3 mg/kg
IM, SC
Butorphanol 0.2–0.4 mg/kg
Protocols 114
Respiratory compromise
Transition phase
Post-induction inhalant rates
Inhalant Rates Miscellaneous
50–100 mL/kg/minute
(rebreathing) For first 15 minutes
Oxygen
150–300 mL/kg/minute after induction
(NRB)
Large dogs may
Sevoflurane 3% for 3 minutes
need higher rates
■ Be prepared to perform manual ventilation
● Closely watch the manometer to ensure pressures do not
exceed 12–15 cm H2O as lung compliance may be reduced
■ Monitor anesthetic depth and oxygenation closely
115 Book 3
Respiratory compromise
Anesthetic maintenance
Inhalant Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
■ Be prepared to adjust oxygen flow rates in response to patient
clinical parameters
■ Amount of sevoflurane will vary with patient health, analgesic
therapy and local blocks used
■ If 4% or more sevoflurane is required:
● Check the anesthesia system for leaks
● Ensure appropriate analgesia
● Consider:
□ Inadequate premedication
□ Improper endotracheal intubation, etc.
○ See Equipment chapter for more details
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 116
Respiratory compromise
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
117 Book 3
Respiratory compromise
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally
SpO2 95–100%
on room air
Sternal recumbency
Pain controlled Pain score <2
■ Patients with chronic respiratory disease may have SpO2 levels below
and EtCO2 levels above the normal range
● Upon recovery, SpO2 levels should return to preoperative levels
■ Supplemental oxygen may be of benefit to these patients in the
recovery phase and can be provided by flow by/mask/oxygen cage
(where available)/instillation of nasal oxygen tubes
● Flow-by O2 support is inefficient and should only be utilized if the
patient will not calmly tolerate the mask
Protocols 118
Respiratory compromise
119 Book 3
Respiratory compromise
Protocols 120
Respiratory compromise
Analgesia to go home
Drug Dosage Route
NSAID
PO once daily or
Carprofen Canine 4 mg/kg divided into 2 doses
for 3–5 days
Meloxicam Canine 0.1 mg/kg PO, every 24 hours
PO once daily for a
maximum of 3 total
Robenacoxib Feline 1 mg/kg doses over 3 days.
Do not exceed
1 dose per day.
OPIOID
Canine 5 mg/kg
Tramadol* PO, every 6 hours
Feline 2–4 mg/kg
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
121 Book 3
Sighthounds
Sighthounds
What is different about this patient?
Sighthounds have unique behavioral and physical characteristics that
will influence anesthetic and monitoring choices.
■ Higher PCV% and lower protein levels which can result in effects of
drugs that are highly protein bound
■ Low body fat increasing the risk for hypothermia under anesthesia
■ Deep chested with a larger chest capacity than other breeds of
similar weights
■ Greyhounds specifically can appear quiet but can be nervous and
develop stress hypertension, hyperthermia and colitis
■ Decreased activity in liver metabolism slowing the clearance of some
drugs such as propofol
■ Pressure injuries occur easily from improper positioning or padding
■ Skin is easily lacerated or damaged
Protocols 122
Sighthounds
Premedication
Drug Dose Route
Butorphanol 0.2 mg/kg
IM
Acepromazine 0.05 mg/kg
OR
Butorphanol 0.2 mg/kg IM
IM
Dexmedetomidine 2.5 mcg/kg
■ Reduce acepromazine or dexmedetomidine doses in older or
quiet patients
■ Only using opioids may predispose to dysphoria in recovery
■ If analgesic therapy is warranted, replace butorphanol in
the premedication with another opioid listed in Additional
Analgesic Therapy
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
123 Book 3
Sighthounds
Protocols 124
Sighthounds
Transition phase
Post-induction inhalant rates
Anesthetic Maintenance
Drugs Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
■ Be prepared to adjust oxygen flow rates in response to patient
clinical parameters
■ Amount of sevoflurane will vary with patient health, analgesic
therapy and local blocks used
■ If 4% or more sevoflurane is required:
● Check the anesthesia system for leaks
● Ensure appropriate analgesia
● Consider:
□ Inadequate premedication
□ Improper endotracheal intubation, etc.
○ See Equipment chapter for more details
125 Book 3
Sighthounds
Anesthetic recovery
Anesthetic Recovery Parameter
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
Protocols 126
Sighthounds
127 Book 3
Sighthounds
Analgesia to go home
Drug Dosage Route
NSAID
PO once daily
Carprofen Canine 4 mg/kg or divided into 2
doses for 3–5 days
Meloxicam Canine 0.1 mg/kg PO, every 24 hours
OPIOID
Tramadol* Canine 5 mg/kg PO, every 6 hours
*Oral tramadol has not been shown to be effective postoperatively in dogs
■ NSAID and/or opioid as appropriate for health status
■ Dispense the same NSAID that was utilized postoperatively
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Protocols 128
Sighthounds
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
129 Book 3
Soft tissue (elective)
Examples
Castration Ovariohysterectomy
Mass removal Laceration repair
Protocols 130
Soft tissue (elective)
Premedication
Drug Dose Route
Midazolam 0.1–0.3 mg/kg
IM, SC
Butorphanol 0.2–0.4 mg/kg
OR
Acepromazine 0.02–0.05 mg/kg
IM, SC
Butorphanol 0.2–0.4 mg/kg
131 Book 3
Soft tissue (elective)
Transition phase
Post-induction inhalant rates
Protocols 132
Soft tissue (elective)
Anesthetic Maintenance
Drugs Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
■ Be prepared to adjust oxygen flow rates in response to patient
clinical parameters
■ Amount of sevoflurane will vary with patient health, analgesic
therapy and local blocks used
■ If 4% or more sevoflurane is required:
● Check the anesthesia system for leaks
● Ensure appropriate analgesia
● Consider:
□ Inadequate premedication
□ Improper endotracheal intubation, etc.
○ See Equipment chapter for more details
133 Book 3
Soft tissue (elective)
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
Protocols 134
Soft tissue (elective)
135 Book 3
Soft tissue (elective)
Analgesia to go home
Drug Dosage Route
NSAID
PO once daily or
Carprofen Canine 4 mg/kg divided into 2 doses
for 3 - 5 days
Meloxicam Canine 0.1 mg/kg PO, every 24 hours
PO once daily for a
maximum of 3 total
Robenacoxib Feline 1 mg/kg doses over 3 days.
Do not exceed 1
dose per day.
OPIOID
Canine 5 mg/kg
Tramadol* PO, every 6 hours
Feline 2–4 mg/kg
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
* Oral tramadol has not been shown to be effective postoperatively in dogs
Protocols 136
Stressed/fractious
Stressed/fractious
What is different about this patient?
This patient will have extremely high levels of circulating
catecholamines (epinephrine, norepinephrine), which can make the
patient prone to sudden cardiovascular collapse (hypotension, cardiac
arrhythmias, shock, organ dysfunction), especially when sedatives and
anesthetics are added. This is sometimes referred to as a “crash.”
Additionally, stressed/fractious patients may be impossible to handle
for a physical exam. The presence of serious disease may be masked
by this physiologic “fight or flight” state, making these patients prone
to crash after sedation or induction when the full extent of underlying
disease becomes known.
Always be prepared for this crash.
Considerations before proceeding to chemical restraint:
■ Most aggressive behavior is a result of underlying fear or pain.
● Provide analgesic therapy as medically indicated.
● It may be in the best interest of the fearful patient to reschedule
the procedure and introduce a counterconditioning program.
■ If the patient struggles for more than three seconds, release and
reposition.
● If struggling for more than three seconds occurs two to three times,
consider chemical restraint or abort the procedure.
● Remember that less may be more in regards to handling and restraint.
137 Book 3
Stressed/fractious
Drug Dose
5–15 mg/kg PO 1hr prior to travel
Protocols 138
Stressed/fractious
Premedication
Drug Dose Route
CANINE
Tiletamine,
2–4 mg/kg
Zolazepam IM
Butorphanol 0.2–0.4 mg/kg
OR
Dexmedetomidine 2–5 mcg/kg
Ketamine 1–2 mg/kg IM
Butorphanol 0.2–0.4 mg/kg
OR
Dexmedetomidine 5–7 mcg/kg IM
Butorphanol 0.2–0.4 mg/kg
OR
Alfaxalone 2 mg/kg IM (volume will limit to
Butorphanol 0.2–0.4 mg/kg small dogs)
139 Book 3
Stressed/fractious
OR
OR
OR
Protocols 140
Stressed/fractious
Note: Unique DKT dosing and directions for use in both canines and felines
■ lfaxalone 2 mg/kg IM can be added to above feline protocols to
achieve more sedation or as an additional IM injection if sedation is not
adequate after 15 minutes
■ Perform physical examination if not able to be completed prior
to premedication
■ Place IV catheter if medically indicated or length of procedure is
anticipated to be longer than 10 minutes
■ Obtain necessary clinical pathology samples
141 Book 3
Stressed/fractious
Transition phase
Post-induction inhalant rates
Anesthetic maintenance
Inhalant Rates
20–30 mL/kg/minute (rebreathing)
Oxygen
200 mL/kg/minute (average rate, NRB)
Sevoflurane 1–4% to effect with oxygen
■ Be prepared to adjust oxygen flow rates in response to patient
clinical parameters
■ Amount of sevoflurane will vary with patient health, analgesic
therapy and local blocks used
■ If 4% or more sevoflurane is required:
● Check the anesthesia system for leaks
● Ensure appropriate analgesia
● Consider:
□ Inadequate premedication
□ Improper endotracheal intubation, etc.
○ See Equipment chapter for more details
Protocols 142
Stressed/fractious
143 Book 3
Stressed/fractious
Anesthetic recovery
Parameter Range
Normothermic Temp 100–102.5° F
Normotensive MAP 80–100 mm Hg
Oxygenating normally on room air SpO2 95–100%
Sternal recumbency
Pain controlled Pain score <2
Protocols 144
Stressed/fractious
145 Book 3
Stressed/fractious
Analgesia to go home
Drug Dosage Route
NSAID
PO once daily
Carprofen Canine 4 mg/kg or divided into 2
doses for 3–5 days
Meloxicam Canine 0.1 mg/kg PO, every 24 hours
PO once daily for a
maximum of 3 total
Robenacoxib Feline 1 mg/kg doses over 3 days.
Do not exceed 1
dose per day.
OPIOID
Canine 5 mg/kg
Tramadol PO, every 6 hours
Feline 2–4 mg/kg
Transmucosal,
Buprenorphine Feline 0.01–0.02 mg/kg
every 8 hours
Protocols 146
Stressed/fractious
Addendum:
Special considerations for surgery:
Ear/Aural Tissue
Induce healthy patients for aural surgery with tiletamine, zolazepam
1–2 mg/kg IV, rather than propofol. Dilute with sterile water to a volume
of 1–3 mL and give slowly to effect for intubation. Watch closely for
signs of patient readiness for intubation as described in the Induction,
Monitoring and Recovery chapter.
Tiletamine might be helpful with neuropathic pain, which may be
present with aural surgery.
These patients may be expected to have more significant analgesic
requirements. Consider:
■ Wound infusion catheters
■ Constant rate infusions (CRIs)
■ See Appendix chapter for details of advanced analgesic techniques
Avoid acepromazine
Maintain EtCO2 between 28–35 for patients with head trauma.
Avoid increasing intracranial pressure:
■ Vomiting
■ Coughing
■ Jugular vein occlusion
■ Recumbent position with head lowered
■ Medications (e.g., ketamine)
147 Book 3
Stressed/fractious
Hyperthyroidism
ECG and echocardiogram are recommended prior to elective anesthesia.
If unable to pursue, assume the patient has ventricular hypertrophy when
choosing your anesthetic drug and monitoring protocol.
Possible Complications:
■ Bradycardia
■ Hypotension
■ Heart failure
■ Hypoglycemia (higher risk if hyperthyoridism is uncontrolled)
Protocols 148
Stressed/fractious
7. Tranquilli WJ, Thurman JC, Grimm KA. Lumb and Jones’ Veterinary Anesthesia
and Analgesia. 4th edition. Oxford, England. Wiley-Blackwell. 2007;933.
8. Hoskins JD. Veterinary Pediatrics: Dogs and Cats from Birth to Six Months. 3rd
edition. Philadelphia, Pa. Saunders. 2001;525-547.
9. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and
treatment of canine chronic valvular heart disease. J Vet Intern Med. Nov-Dec
2009;23(6):1142-1150.
10. Hall J, Hall K, Powell LL, etal. Outcome of male cats managed for urethral
obstruction with decompressive cystocentesis and urinary catheterization: 47
cats (2009-2012). J Vet Emerg Crit Care. 2015 Mar-Apr;25(2):256-262.
11. Cooper ES. Controversies in the management of feline urethral obstruction. J
Vet Emerg Crit Care (San Antonio). Jan-Feb 2015;25(1):130-137.
12. Stevens BJ , Frantz EM, Orlando JM, et al. Efficacy of a single dose of
trazadone hydrochloride given to cats prior to veterinary visits to reduce
signs of transport- and examination-related anxiety. J Am Vet Med Assoc. July
2016;249(2):202-207.
13. Neilson J. Drug Therapy for Behavioral Problems. Proceedings: 2010 Western
Veterinary Conference. Las Vegas, Nev.
14. Nieves MA, Hartwig P, Kinyon JM et al. Bacterial isolates from plaque and from
blood during and after routine dental procedures in dogs. Vet Surg. 1997 Jan-
Feb 1997;26(1):26-32.
15. Gruen ME, X.Lascelles BD, Colleran E, et al. 2022 AAHA Pain management
Guidelines for Dogs and Cats. J Am Anim Hosp Assoc. 2022; 58:55-76.
16. 16. Brock N. Veterinary Anesthesia Update: Guidelines and Protocols for Small
Animal Anesthesia. 3rd Edition. Nancey Brock. 2000.
17. 17. Greene SA. Veterinary Anesthesia and Pain Management Secrets.
Philadelphia, PA: Haley & Belfus; 2001.
18. 18. Lerche P, Thomas JA. Anesthesia and Analgesia for Veterinary Technicians.
4th Edition. St Louis, MO. Elsevier; 2011.
19. 19. Grubb T, Sager J, Gaynor Jet al. 2020 AAHA Anesthesia and Monitoring
Guidelines for Dogs and Cats. J AM Anim Hosp Assoc. 2020;56.
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
149 Book 3
CPR Clinical
Guidelines
This chapter is comprised of excerpts taken from the Reassessment
Campaign on Veterinary Resuscitation (RECOVER) guidelines,
published in the Journal of Veterinary Emergency and Critical Care,
and used with permission from John Wiley and Sons, Inc., publisher.
Note: Information regarding defibrillation therapy and open chest
cardiopulmonary resuscitation (CPR) is not included in this text
Abbreviations
CPR 150
Preparedness and prevention
Equipment
■ Equipment and supply inaccessibility or failure has been implicated
in delays in initiation of CPR in up to 18 percent of cardiopulmonary
arrest (CPA) cases.
■ The location, storage and content of resuscitation equipment
should be standardized and regularly audited (see Medical Quality
Standards chapter for essential equipment and medications).
Resuscitation aids
■ The presence of cognitive aids (checklists, algorithm charts and
dosing charts) has been shown to improve compliance with CPR
guidelines.
■ Formal training of team members in the use of these aids is crucial
for effective utilization during a crisis.
■ Availability and clear visibility of charts and other resuscitation aids
in areas where CPA may occur (procedure areas, surgery suites) is
recommended.
Training
■ Adherence to CPR guidelines can only be accomplished if team
members receive effective, standardized training and regular
opportunities to refresh skills.
■ Regardless of the type of technology used for initial training,
refresher training at least every six months is recommended to
reduce the risk of skill decay.
■ Improved learning outcomes have been documented when CPR
training culminates in performance testing.
■ Regardless of the methods used for initial and refresher training,
structured assessment after CPR training is recommended.
Clinical essential
A CPR team is available during
normal hours of operation
151 Book 3
■ In addition to assessment after didactic and psychomotor skills training,
structured debriefing after a real resuscitation effort or simulated CPR,
allowing participants to review and critique their performance and the
performance of the team as a whole, is recommended.
■ Open, honest discussion about opportunities for improvement
immediately after a CPR attempt can lead to significant
enhancement in CPR performance.
■ Regardless of the status of the CPR team leader (veterinarian or
technician), there is strong evidence that communication and team
skills training can improve the effectiveness of a CPR attempt.
■ Specific leadership training is recommended for team members who
may lead a CPR attempt.
● Crucial roles of the CPR team leader include:
□ Distributing tasks to other team members
□ Enforcing rules and procedures
■ Important leadership behaviors that can improve CPR team
performance include:
● Intermittently summarizing the code to ensure a shared mental
model among team members
● Actively soliciting input from team members to encourage situation
awareness and identify issues and ideas from all team members
● Assigning individual tasks to team members rather than performing
them personally to allow better attention to the global status of the
code
■ Team performance can be enhanced by using focused, clear
communication directed at individuals when tasks are assigned and
utilization of closed loop communication.
● Closed loop communication is accomplished by a clear, directed
order being given to one team member by another, after which the
receiving team member repeats the order back to the requestor to
verify the accuracy of the receiver’s perception.
■ There is high-level and high-quality supportive evidence
in veterinary medicine that anesthesia-related CPAs are
associated with increased survival compared to arrests from
other causes.
CPR 152
Basic Life Support (BLS)
It is imperative that BLS is provided immediately upon diagnosis or
suspicion of CPA.
Definition
■ Recognition of CPA
■ Administration of chest compressions
■ Airway management and provision of ventilation
Recognition
■ It is reasonable to utilize continuous electrocardiogram (ECG) and
arterial blood flow monitoring in at-risk pets.
■ Continuous end-tidal carbon dioxide (EtCO2) monitoring is
recommended in intubated and ventilated at-risk pets.
■ Monitored pulse sounds are not a reliable tool for the diagnosis
of cardiac arrest, although their disappearance may indicate
impending arrest in pets in which the probe was placed prior to CPA.
● In anesthetized pets, the loss of pulse sounds may be a reasonable
indicator of profound hemodynamic deterioration or CPA.
■ In anesthetized pets (monitored with an ECG prior to CPA) where
physical signs of CPA (unconsciousness, apnea) are not available,
ECG alterations may prove helpful as a supporting diagnostic tool
for confirmation of CPA.
■ Since CPA is a clinical diagnosis, it is essential that the ECG is not
regarded as the sole indicator of life or perfusing cardiac rhythm.
■ Aggressive administration of CPR in pets suspected of being in CPA is
recommended, as the risk of injury due to CPR in pets not in CPA is low.
■ When assessing pets that are apneic and unresponsive, a rapid
airway, breathing, circulation (ABC) assessment lasting no more
than five to 10 seconds is recommended.
153 Book 3
Chest compressions
■ Chest compressions should be initiated as soon as possible upon
recognition of CPA. If multiple rescuers are present, airway and
ventilation management should not delay commencement of
chest compressions.
● Ideal chest compressions may achieve a cardiac output of, at
most, approximately 25–30 percent of normal.
■ The immediate provision of chest compressions should be
the priority.
■ Intubation and ventilation should be attempted as soon as possible,
while compressions are being performed.
■ Chest compressions should be done in lateral recumbency
(either left or right) in both dogs and cat.
■ There is strong evidence supporting a recommendation for
compression rates of 100–120/minute in cats and dogs
CPR 154
Ventilation
■ Early endotracheal (ET) intubation and provision of ventilation in
CPR is likely to be beneficial.
■ If equipment and team members are available, rapid intubation of
dogs and cats in CPA is recommended.
● This should be accomplished with the pet in lateral recumbency so
chest compressions may be continued during the procedure.
● Once the ET tube is in place, inflate the cuff so that ventilation and
chest compressions can occur simultaneously.
Ventilation rate:
› A ventilation rate of 10 breaths/minute with a tidal volume of 10 mL/kg
and a short inspiratory time of one second are recommended.
› For single-rescuer CPR, a compression:ventilation (C:V) ratio of 30:2
in non-intubated dogs is recommended.
● Perform a series of 30 chest compressions at a rate of 100–120
compressions/minute.
● Deliver two breaths quickly using the mouth-to-snout technique.
● Perform another series of 30 chest compressions.
› Chest compressions should be performed in two-minute cycles without
interruption in intubated pets when several rescuers are present.
155 Book 3
Advanced life support (ALS)
ALS includes:
› Administration of: › Correction of:
● Vasopressors ● Electrolyte disturbances
● Positive inotropes ● Volume deficits
● Anticholinergic drugs ● Severe anemia
CPR 156
■ In refractory ventricular fibrillation/pulseless ventricular
tachycardia, consider:
● Amiodarone (5 mg/kg IV)
● Lidocaine (2 mg/kg IV)
■ IV calcium may be considered in dogs and cats with documented
moderate to severe hypocalcemia during CPR.
■ Documented hyperkalemia should be treated during CPR.
■ Treatment of documented hypokalemia during CPR may
be considered.
■ The routine use of corticosteroids during CPR is not recommended.
■ Administration of 1 mEq/kg of sodium bicarbonate may be
considered after prolonged CPA of more than 10–15 minutes.
■ For pets in which IV or intraosseous access is not possible, consider
the use of the intratracheal route for epinephrine or atropine.
● Drugs should be diluted with saline or sterile water and
administered via a catheter longer than the ET tube.
■ Use of a fraction of inspired oxygen (FiO2) of 21 percent (room air)
may be considered.
● In the absence of arterial blood gas data, the risks of hypoxemia
likely outweigh the risks of hyperoxemia and the use of a FiO2 of
100 percent is reasonable.
■ In euvolemic or hypervolemic dogs and cats, routine administration
of IV fluids is not recommended.
● Pets with pre-existing hypovolemia are likely to benefit from
increased circulating volume during CPR and administration of IV
fluids in these pets is reasonable.
157 Book 3
Monitoring
End-tidal carbon dioxide (EtCO2)
■ Immediate post-intubation EtCO2 value should not be used for
diagnosis of CPA in dogs and cats.
● Initial values may not be representative of pulmonary perfusion.
□ Subsequent values may be associated with pulmonary perfusion.
● Multiple high-quality studies support the conclusion that sudden
increases in EtCO2 occur rapidly with ROSC (due to increased
pulmonary blood flow).
■ EtCO2 monitoring is likely a valuable adjunct for verification of
correct ET tube placement, in conjunction with:
● Direct visualization
● Auscultation
● Observation of chest excursions
■ EtCO2 should not be used as a sole measure of correct ET tube placement.
■ Evaluation of the ECG (though susceptible to artifact) during
intercycle pauses is recommended to obtain an accurate rhythm
diagnosis and guide ALS therapy.
● Chest compressions should not be stopped during a complete
two-minute cycle of CPR to allow ECG interpretation.
● Pauses in chest compressions to evaluate the ECG rhythm should
be minimized.
■ There is strong evidence supporting the use of EtCO2 monitoring
during CPR as an early indicator of ROSC and as a measure of
efficacy of CPR.
● Potentially allows rescuers to adjust treatment to maximize perfusion
Pulse
■ Interruption of chest compressions during CPR specifically to
palpate the pulse is not recommended.
■ Palpation of the pulse to identify ROSC during intercycle pauses in CPR
is reasonable as long as it does not delay resumption of compressions.
CPR 158
Electrolytes
■ Routine monitoring of electrolytes, especially during prolonged CPR,
may be considered.
■ In cases of CPA that are known or suspected to be due to electrolyte
derangements, monitoring of electrolytes will help guide therapy and
is recommended.
Additional
■ Central or mixed venous blood gas analysis to evaluate the
effectiveness of CPR may be considered but arterial blood gas
analysis during CPR is not recommended.
■ Due to the high risk of recurrence, post-resuscitation monitoring should
be sufficient to detect impending reoccurrence of CPA and should be
sufficient to guide therapy appropriate for the pet’s condition.
■ There is no clear evidence to delineate between recommendations for
continuous monitoring versus intermittent monitoring.
● Monitoring should be tailored to the individual pet and its
circumstances and underlying diseases, especially when
determining the intervals for intermittent monitoring.
■ There is evidence in support of serial monitoring following ROSC of:
● Continuous ECG
● Arterial oxygenation
● Ventilation
● Body temperature
● Blood glucose
● Systemic (arterial) blood pressure
● Serial physical exams and neurologic monitoring
■ Serial body temperature measurements are recommended to avoid
high rewarming rates and hyperthermia.
■ In one veterinary study, 54 percent of pets that achieved
ROSC succumbed to another episode of CPA, highlighting the
importance of post-cardiac care and monitoring.
159 Book 3
Post-cardiac arrest (PCA) care
CPR 160
■ It is reasonable to employ manual or mechanical ventilation in the
PCA period in pets that:
● Are hypoventilating
● Are hypoxemic
● Require high inspiratory oxygen concentration (FiO2 equal to or
greater than 60 percent) to maintain normoxemia
● Are at risk of respiratory arrest
■ Both hypoxemia and hyperoxemia should be avoided.
■ If mild accidental hypothermia is present in the PCA period, it is
reasonable to not rapidly rewarm these pets.
● Mild therapeutic hypothermia should not be initiated if advanced
critical care capabilities, including mechanical ventilation, are
not available.
■ Routine administration of corticosteroids during PCA care is
not recommended.
● Administration of hydrocortisone (1 mg/kg followed by either
1 mg/kg every six hours or an infusion of 0.15 mg/kg/hour and
then tapered as the pet’s condition allows) to cats or dogs that
remain hemodynamically unstable despite administration of fluids
and inotropes/pressors during PCA care may be considered.
Equivalent dexamethasone sodium phosphate dosing is roughly
0.5 mg/kg IV.
■ Use of hypertonic saline and mannitol in dogs and cats with neurologic
signs consistent with cerebral edema (e.g., coma, cranial nerve deficits,
decerebrate postures, abnormal mentation) may be considered.
■ Referral of critically ill dogs and cats to facilities with intensive
monitoring and advanced therapeutics for PCA care is reasonable.
Clinical essential
Offer referral of critical or unstable
pets to owners when appropriate and
in the best interest of the pet
161 Book 3
Figure 3.1
Cardiopulmonary Resuscitation
Cardiopulmonary Arrest
(CPA)
Evaluate Patient
Return of Spontaneous
Circulation
Change Compressor
every 2 minutes
For additional information see RECOVER guidelines, CPR chapter and supporting materials.
CPR 162
Figure 3.2
INITIATE
1 ECG MONITORING
2 EtCO2 MONITORING (where equipment exists)
3 ENSURE PATENT VASCULAR ACCESS
4 ADMINISTER REVERSAL AGENTS (if appropriate)
VASOPRESSOR DRUGS
DRUG DOSE NOTES
Epinephrine Administer every other cycle
0.01 mg/kg
(1 mg/mL) Consider 0.1 mg/kg with CPA >10 min
Atropine Administer every other cycle with
0.05 mg/kg
(0.54 mg/mL) asystole or pulseless electrical activity
ANTI-ARRHYTHMIC DRUGS
Amiodarone Used for ventricular fibrillation and
5 mg/kg
(50 mg/mL) ventricular tachycardia
Lidocaine
(20 mg/mL) Canine: 2–8 mg/kg Canine: 8 mg/kg
Maximum doses:
if amiodarone Feline: 0.2 mg/kg Feline: 1 mg/kg
is not available
163 Book 3
MONITOR
PARAMETER NOTES
Continuous ECG Normal sinus rhythm; assess for ROSC
EtCO2 >15 mm Hg indicates good compressions
SpO2 >90 % breathing room air or 100% O2
Ensure monitoring does not impede
TPR
compressions and ventilation
Blood pressure MAP >80 mm Hg
Blood glucose >100 mg/dL
Serial physical and neurologic examinations
ASSESS
PARAMETER NOTES
Calcium Correct if needed
Potassium Correct if needed
Volume status Administer fluids if hypovolemic
Inhalant rates of 21 - 100%;
FiO2
adjust based on SpO2
Consider sodium bicarbonate therapy
Acid base status
(1 mEq/kg) if CPA >10 min
Clinical essential
Crash cart containing emergency
drugs and equipment is readily available,
in a designated place, portable, clearly
labeled and appropriately stocked at
all times
165 Book 3
References and suggested reading for CPR:
1. McMichael M, Herring J, Fletcher DJ, et al. RECOVER evidence and
knowledge gap analysis on veterinary CPR. Part 2: Preparedness and
prevention. J Vet Emerg Crit Care (San Antonio). 2012;22(S1):13-25.
2. Hopper K, Epstein SE, Fletcher DJ, et al. RECOVER evidence and knowledge
gap analysis on veterinary CPR. Part 3: Basic life support. J Vet Emerg Crit
Care. 2012;22(S1):26-43.
3. Rozanski EA, Rush JE, Buckley GJ, et al. RECOVER evidence and knowledge
gap analysis on veterinary CPR. Part 4: Advanced life support. J Vet Emerg
Crit Care. 2012;22(S1):44-64.
4. Brainard BM, Boller M, Flectcher DJ, et al. RECOVER evidence and
knowledge gap analysis on veterinary CPR. Part 5: Monitoring. J Vet Emerg
Crit Care. 2012;22(S1):65-84.
5. Smarick SD, Haskins SC, Boller M, et al. RECOVER evidence and knowledge
gap analysis on veterinary CPR. Part 6: Post-cardiac arrest care. J Vet
Emerg Crit Care 2012;22(S1):85-101.
6. Scott-Moncrieff JC. Hypoadrenocorticism in dogs and cats: Update on
diagnosis and treatment. Proceedings ACVIM Forum 2010, Anaheim, Calif.
Full RECOVER articles are available online with open access at:
www.onlinelibrary.wiley.com/doi/10.1111/vec.2012.22.issue-s1/issuetoc
Job aids, posters and charts are available at the Veterinary Emergency
and Critical Care Society (VECCS) website:
www.veccs.org/product-category/posters/
CPR 166
APPENDIX
Abbreviations
Medication dilution
and combination
■ Completely label and date all medication dilutions and combinations
with the appropriate labels
■ Follow local, state and/or federal law for the mixing, storage and
disposal of all medications and controlled drugs
167 Book 3
■ All CRIs:
● Prepared directly at the time of use
■ Dedicated to one patient
● Discarded immediately when no longer in use
■ Completely label and date all syringes with the appropriate label.
Resultant
Medication Dilution
Solution
Sterile Mix 27mL sterile water
Acepromazine 1 mg/mL
vial 3 mL (30 mg) acepromazine
1 mL dexmedetomidine
Sterile (0.5 mg)
DKT
vial 1 mL ketamine (100 mg)
1 mL butorphanol (10 mg)
● Stability and length of efficacy of diluted or combination
medications have only been determined in a limited number of
animal species and for a minimal amount of medications1,2,3
● Follow the intravenous access requirements for multi-dose vial usage:
□ Use amber-colored glass vials to protect contents from light.
□ Use aseptic technique every time, with every instance of
handling.
□ Discard immediately if any signs of gross contamination.
□ Obtain a new, sterile syringe and needle for each use.
□ Discard syringe and needle after each use.
Appendix 168
■ Except where prohibited by law, it is recommended to:
● Check all medication vials prior to use to ensure medications are
not expired prior to diluting or mixing and to ensure expiration
dates will not be exceeded with storage.
● Keep medications that have been diluted or mixed at room
temperature and protect from light.
● Discard any unused medications (following appropriate laws for
disposal) after 28 days.
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
169 Book 3
Constant Rate Infusions (CRIs)
Dexmedetomidine CRI
■ Post-operative/recovery/sedative/anxiety treatment if analgesics
have been administered and pet is showing signs of stress or anxiety
■ Has synergistic effects with opioid analgesics and decreases
perioperative stress in dogs
■ Provides analgesia through both central and peripheral mechanisms
■ Should not be considered a “standalone” analgesic
● Should be used in conjunction with opioid analgesics to take
advantage of synergistic effects
■ May be used as a treatment option for opioid dysphoria
■ May help with neuropathic pain
■ Should be administered via syringe or fluid pump
Dose:
› Recommended dose range is 0.5–2.0 mcg/kg/hour (canine and feline)
● 1.0 mcg/kg/hour is most commonly used
*Patients should be monitored for level of sedation and rousability and infusion
rate decreased accordingly
Appendix 170
Fentanyl CRI
■ Fentanyl is very short acting (approximately 15 minutes) and
therefore requires CRI administration.
■ Major advantage of a fentanyl CRI is that it allows titration of opioid
dosing to pet needs.
■ Fentanyl may decrease the inhalant requirements up to
approximately 65 percent depending on dose.
● It is very important that the inhalant be titrated accordingly
to avoid the pet being too deep.
■ Fentanyl should be administered via syringe pump.
■ If hydromorphone premedication dose was administered within
2 hours, a fentanyl loading dose is not required.
● If not, then administer a fentanyl loading dose of 3–5 mcg/kg
slowly over 2 minutes while monitoring pulse/HR via ECG and
respiration to rapidly achieve analgesic plasma levels
Heart rate:
■ If significant bradycardia is associated with hypotension
(MAP <60 mm Hg) then administer an anticholinergic (glycopyrrolate
0.005 mg/kg IV or 0.01 mg/kg IM).
● Significant bradycardia; less than 50 bpm in medium to large
dogs, less than 70–80 bpm in small dogs and cats.
Respiration:
■ Monitor saturation of peripheral oxygen (SpO2) at transition
from 100% oxygen to room air at recovery.
● Provide supplemental O2 (100 mLs/kg/min) until able to maintain
SpO2 >93–95%.
■ End-tidal carbon dioxide (EtCO2) should be monitored and manual or
mechanical intermittent positive pressure ventilation (IPPV) provided
if EtCO2 is greater than 55 mm Hg, despite titration of inhalant.
171 Book 3
Level of sedation:
■ Ensure that patient is ‘rousable’ and can respond to his/her name.
If not:
● May be prone to hypoventilation/hypoxemia, regurgitation/
aspiration
□ Lower/stop CRI, assess pulse/HR, respiration, SpO2
(provide supplemental O2 if <93%).
□ Partial reversal with butorphanol 0.1 mL (1.0 mg) diluted in
0.9 mLs IV fluid, given in 0.2 mL increments IV
Body temperature:
■ If hypothermic, provide active heating
Assessment of pain:
■ Adjust CRI based on pain level
Dose:
Loading dose:
3.0 - 5.0 mcg/kg IV slowly over 2 minutes, monitor pulse/heart rate
(HR) via electrocardiography (ECG) and respiration
CRI:
Intra-op: 5.0–10 mcg/kg/hr*
Post-op: 2.0–10 mcg/kg/hr*
*The reported analgesic plasma levels of fentanyl in dogs are 1.0 -2.0 ng/mL.
Appendix 172
Hydromorphone, Lidocaine, Ketamine (HLK) CRI
■ Intra-operative constant rate infusion (CRI) for multimodal analgesia
■ Administer via a fluid or syringe pump:
● Ensure accurate dosing
● Decrease the chance of inadvertent bolus administration
Intra-operative Dose:
› Infuse at 10 mLs/kg/hour for the first hour then reduce to 5.0 mLs/kg/hr
■ DO NOT BOLUS!
■ Add to 1.0 liter bag of crystalloid fluids (all drug volumes and
milligrams can be halved if adding to a 500 mL bag of crystalloids):
173 Book 3
Post-operative Dose:
› Infuse at 2.0 mLs/kg/hour
■ DO NOT BOLUS!
Volume to
Drug Infusion dose
add (mg)
Hydromorphone
0.5 mLs (5.0 mg) 0.01 mg/kg/hr
(10 mg/mL)
Lidocaine 1.5 mg/kg/hr
37.5 mLs (750 mg)
(20 mg/mL) (25 mcg/kg/min)
Ketamine 0.12 mg/kg/hr
0.6 mLs (60 mg)
(100 mg/mL) (2.0 mcg/kg/min)
Supplemental Information:
■ When patients have significant analgesic requirements, and an HLK
CRI is planned, loading doses of medications may be considered
prior to induction.
■ Remember the caveats for these patients.
■ Lidocaine
● Provide loading dose for intra-operative CRI
□ 2.0 mg/kg slowly IV over 2 minutes prior to induction
■ Ketamine
● Can be administered after lidocaine and prior to propofol to
provide a loading dose for intra-operative CRI
□ 0.5 mg/kg slowly IV
■ Note that the use of these medications may impact (reduce)
the amount of induction agent needed to achieve intubation.
Note: There are multiple formulas that may be used for calculations of
CRIs. Examples using a syringe pump or a 250 mL fluid bag for infusion
are provided here. See individual chapters and additional content in the
Appendix for details. It is the attending veterinarian's responsibility to
correctly calculate and administer CRIs. Concentrations may need to
vary based upon patient size. Pay close attention to fluid administration
rates and the potential for fluid overload.
Appendix 174
Table 3.1
Resultant
Medication Infusion
Solution
Dexmedetomidine Syringe Mix 30 mL sterile 5 mcg/mL
(0.5 mg/mL) pump 0.9% NaCl with
0.3 mL (0.15 mg)
dexmedetomidine
250 mL Add 2.5 mL (1.25 mg)
bag dexmedetomidine to
0.9% NaCl new, sterile bag
Dobutamine Syringe Mix 30 mL sterile 12.5
(12.5 mg/mL) pump 0.9% NaCl with mcg/mL
0.03 mL (0.375 mg)
dobutamine
250 mL Add 0.25 mL (3.125
bag mg) dobutamine to
0.9% NaCl new, sterile bag
Dopamine Syringe Mix 30 mL sterile 0.9% 40 mcg/mL
(40 mg/mL) pump NaCl with 0.03 mL (1.2
mg) dopamine
250 mL Add 0.25 mL (10 mg)
bag dopamine to new,
0.9% NaCl sterile bag
Fentanyl Syringe Mix 30 mL sterile 0.9% 2.5 mcg/
(0.5 mg/mL) pump NaCl with 0.15 mL mL
(0.075 mg) fentanyl
250 mL Add 1 mL (0.5 mg) 2 mcg/mL
bag fentanyl to new,
0.9% NaCl sterile bag
Lidocaine Syringe Mix 30 mL sterile 0.9% 2 mg/mL
(20 mg/mL) pump NaCl with 3 mL (60
CRI mg) lidocaine
250 mL Add 12.5 mL (250 mg) 1 mg/mL
bag 0.9% lidocaine to new,
NaCl sterile bag
175 Book 3
Fentanyl Patch
■ Recommended dose is 4 mcg/kg/hour (canine)
■ In cats, a 25 mcg/hour patch is applied resulting in doses ranging
from 4–8 mcg/kg.
■ Analgesia has been associated with plasma concentrations of
~0.6–1.2 ng/mL in dogs and 1.5–1.7 ng/mL in cats which can take up
to 24 hours in dogs and 7 hours in cats.5
● There is significant inter-individual variability in plasma
concentrations achieved with fentanyl patches, therefore, patients
should be assessed for adequate analgesia using the Colorado
Acute Pain Scale.
■ Plans for alternative mu-opioid analgesia should be made until the
expected onset of adequate analgesic plasma levels.
● Buprenorphine (partial mu agonist) and butorphanol
(mu antagonist) will antagonize the effects of fentanyl and
should not be used concurrently.
● Hydromorphone or fentanyl CRI are recommended.
■ Fentanyl patches should be placed at recovery from general
anesthesia to avoid excessive absorption due to external pet warming
devices.
■ Apply to dorsal/lateral thorax.
● Consider patient access to licking or ingesting patch when
planning site of application.
■ Clip hair, wipe excess hair (rolled self-adherent wraps work well),
warm with hands, apply.
■ Fentanyl patches are typically removed by ~72 hours post application.
■ Patches that lift off of the skin should be replaced on a newly
prepared area of skin.
■ If an animal ingests a patch, it should be monitored for signs
of opioid overdosage and naloxone (mu antagonist) should be
administered.
■ Proper disposal is imperative.
Appendix 176
Wound Infusion Catheters
■ Flexible, polypropylene, perforated, indwelling catheters imbedded in
or near surgical sites and used to deliver intermittent injections of
local anesthetics
■ Major advantages:
● Provide local pain relief
● Reduce the need for systemic analgesics
● Faster return of appetite
● Ambulatory the evening of or morning after surgery
□ Require less nursing care as patients are able to walk outside for
elimination needs
■ Less parenteral analgesic requirement reduces side effects:
● Sedation
● Risk of regurgitation/aspiration
● Urinary retention
■ Clinical investigations of this technique in human medicine
have demonstrated:
● Improved pain control at rest and with activity
● Decreased opioid requirement
● Increased patient satisfaction
● Shorter hospital stay following a variety of surgical procedures
■ Studies in animals describe uses for:
● Ear canal ablation
● Median sternotomy
● Lateral thoracotomy
● Limb amputation
● Major soft tissue tumor excision:
□ Mastectomy
□ Fibrosarcoma resection in cats
177 Book 3
Equipment:
■ Butterfly connectors
■ Wound infusion catheter (Figures 3.5 and 3.6)
● The distal tip of the wound infusion catheter is sealed so that liquid
exits only from the micropores.
● The catheters are available with different lengths of micropores to
allow for use in a variety of anatomical sites and sizes of pets.
● A black depth indicator marks a point located ½ inch (1.25 cm)
from the first micropore to insure that all micropores are located
below the skin.
■ Line filter
■ Waterproof dressing
■ Suture
Used with permission from Bonnie L. Hay Kraus, DVM, DACVS, DACVAA
Used with permission from Bonnie L. Hay Kraus, DVM, DACVS, DACVAA
Appendix 178
Technique:
■ Plan for the location of the catheter end/filter/cap.
■ Make a stab incision in the skin, insert the catheter tip and pull the
catheter tip into the wound bed normograde.
■ Insert the catheter with the distal tip in the deepest layer of the
closure and then suture in place.
■ It is essential that all perforations are below the skin.
■ Perform routine wound closure over the catheter.
■ Place a purse string suture and finger trap to secure the catheter.
■ Suture both butterfly connectors to the skin. One should be adjusted
to be located close to the exit of the catheter from the skin to help
keep it from backing out. Cover with sterile, waterproof dressing and
seal the catheter end with a 0.2 micron filter and an injection cap.
Add a clear label to the soaker catheter site to avoid confusion with
an IV injection cap.
179 Book 3
Figure 3.8
Notes
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
Appendix 180
Points to Remember:
› Bury the catheter in deepest part of wound/incision
› Ensure that all micropores are below the skin
› Secure the catheter with a purse string and finger trap and both
plastic tabs
› Administer bupivacaine every four to six hours
› The priming volume for all wound infusion catheters is 0.8 mL and
filters are 1 mL
› Maintain catheter for minimum of 24 - 72 hours and up to three to
five days
› Infuse with bupivacaine 1.5 mg/kg prior to catheter removal to
extend the duration of analgesia
› Assess individual pet for:
● Fluid accumulation. Decrease infusion volume or increase
dosing interval
● Pain assessment of the pet at regular intervals
● Tenderness to palpation. Dose more frequently (reaction to
injection can be seen when dosing interval is every six hours).
● Lower opioid doses. Use of wound infusion catheters will lower
opioid dose requirements. More signs of opioid dysphoria
(or other opioid side effects such as sedation) may be observed
if full opioid doses are used.
181 Book 3
Dosage Charts
The charts are meant to provide a guideline to dosing calculations and
typically list the minimum and maximum dosages for a given medication.
It is the responsibility of the providing veterinarian to decide drug
dosages for an individual patient and perform accurate calculations.
Acepromazine 1 mg/mL
CANINE FELINE
mLs to administer mLs to administer
Weight
(kg) Low end High end Low end High end
0.005 mg/kg 0.05 mg/kg 0.01 mg/kg 0.1 mg/kg
0.5 0.00 0.03 0.01 0.05
1 0.01 0.05 0.01 0.10
2 0.01 0.10 0.02 0.20
3 0.02 0.15 0.03 0.30
4 0.02 0.20 0.04 0.40
5 0.03 0.25 0.05 0.50
6 0.03 0.30 0.06 0.60
7 0.04 0.35 0.07 0.70
8 0.04 0.40 0.08 0.80
9 0.05 0.45 0.09 0.90
10 0.05 0.50 0.10 1.00
11 0.06 0.55
12 0.06 0.60
13 0.07 0.65
14 0.07 0.70
15 0.08 0.75
16 0.08 0.80
17 0.09 0.85 MAXIMUM DOSAGE
18 0.09 0.90
19 0.10 0.95 Canine:
20 0.10 1.00
21 0.11 1.05 2 mg/dog
22 0.11 1.10
23 0.12 1.15 Feline:
24 0.12 1.20
25 0.13 1.25 1 mg/cat
26 0.13 1.30
27 0.14 1.35
28 0.14 1.40
29 0.15 1.45
30 0.15 1.50
31 0.16 1.55
32 0.16 1.60
33 0.17 1.65
34 0.17 1.70
35 0.18 1.75
36 0.18 1.80
37 0.19 1.85
38 0.19 1.90
39 0.20 1.95
40 0.20 2.00
40 + 0.20 2.00
Appendix 182
Alfaxalone 10 mg/mL
CANINE/FELINE
mLs to administer
Weight
(kg) Low end High end
1 mg/kg 4 mg/kg
0.5 0.05 0.2
1 0.1 0.4
2 0.2 0.8
3 0.3 1.2
4 0.4 1.6
5 0.5 2.0
6 0.6 2.4
7 0.7 2.8
8 0.8 3.2
9 0.9 3.6
10 1.0 4.0
11 1.1 4.4
12 1.2 4.8
13 1.3 5.2
14 1.4 5.6
15 1.5 6.0
16 1.6 6.4 SEE DOSING
17 1.7 6.8
18 1.8 7.2 INSTRUCTIONS
19 1.9 7.6 IN TEXT
20 2.0 8.0
21 2.1 8.4 Administer only
22 2.2 8.8 to effect
23 2.3 9.2
24 2.4 9.6
25 2.5 10.0
26 2.6 10.4
27 2.7 10.8
28 2.8 11.2
29 2.9 11.6
30 3.0 12.0
31 3.1 12.4
32 3.2 12.8
33 3.3 13.2
34 3.4 13.6
35 3.5 14.0
36 3.6 14.4
37 3.7 14.8
38 3.8 15.2
39 3.9 15.6
40 4.0 16.0
41 4.1 16.4
42 4.2 16.8
43 4.3 17.2
44 4.4 17.6
45 4.5 18.0
46 4.6 18.4
47 4.7 18.8
48 4.8 19.2
49 4.9 19.6
50 5.0 20.0
183 Book 3
Atipamezole 5 mg/mL
FELINE
mLs to administer
Weight
(kg) Compromised Healthy
0.012 mL/kg 0.021 mL/kg
0.5 0.01 0.01
1 0.01 0.02
2 0.02 0.04
3 0.04 0.06
4 0.05 0.08
5 0.06 0.11
6 0.07 0.13
7 0.08 0.15
8 0.10 0.17
9 0.11 0.19
10 0.12 0.21
11 0.13 0.23
12 0.14 0.25
13 0.16 0.27
Feline:
Reversal for DKT
Canine:
Reversal of dexmedetomidine
Administer atipamezole IM
at equal mL volume to
dexmedetomidine administered
Appendix 184
Atropine 0.4 mg/mL (For cardiac support)
CANINE/FELINE
mLs to administer
Weight
(kg) Low end High end
0.02 mg/kg 0.04 mg/kg
0.5 0.025 0.05
1 0.05 0.1
2 0.10 0.2
3 0.15 0.3
4 0.20 0.4
5 0.25 0.5
6 0.30 0.6
7 0.35 0.7
8 0.40 0.8
9 0.45 0.9
10 0.50 1.0
11 0.55 1.1
12 0.60 1.2
13 0.65 1.3
14 0.70 1.4
15 0.75 1.5
16 0.80 1.6
17 0.85 1.7
18 0.90 1.8
19 0.95 1.9
20 1.00 2.0
21 1.05 2.1
22 1.10 2.2
23 1.15 2.3
24 1.20 2.4
25 1.25 2.5
26 1.30 2.6
27 1.35 2.7
28 1.40 2.8
29 1.45 2.9
30 1.50 3.0
31 1.55 3.1
32 1.60 3.2
33 1.65 3.3
34 1.70 3.4
35 1.75 3.5
36 1.80 3.6
37 1.85 3.7
38 1.90 3.8
39 1.95 3.9
40 2.00 4.0
41 2.05 4.1
42 2.10 4.2
43 2.15 4.3
44 2.20 4.4
45 2.25 4.5
46 2.30 4.6
47 2.35 4.7
48 2.40 4.8
49 2.45 4.9
50 2.50 5.0
185 Book 3
Bupivacaine 5 mg/mL (For local anesthesia)
CANINE FELINE
mLs to administer mLs to administer
Weight Maximum Maximum
(kg) Low end Low end
Dose Dose
1 mg/kg 1 mg/kg
2 mg/kg 1.5 mg/kg
0.5 0.10 0.20 0.10 0.15
1 0.20 0.40 0.20 0.30
2 0.40 0.80 0.40 0.60
3 0.60 1.20 0.60 0.90
4 0.80 1.60 0.80 1.20
5 1.00 2.00 1.00 1.50
6 1.20 2.40 1.20 1.80
7 1.40 2.80 1.40 2.10
8 1.60 3.20 1.60 2.40
9 1.80 3.60 1.80 2.70
10 2.00 4.00 2.00 3.00
11 2.20 4.40 2.20 3.30
12 2.40 4.80 2.40 3.60
13 2.60 5.20 2.60 3.90
14 2.80 5.60
15 3.00 6.00
16 3.20 6.40
17 3.40 6.80
18 3.60 7.20
19 3.80 7.60
20 4.00 8.00
21 4.20 8.40 LOCAL INJECTION
22 4.40 8.80
23 4.60 9.20 GUIDELINES
24 4.80 9.60
25 5.00 10.00 Canine:
26 5.20 10.40
27 5.40 10.80 0.5 - 1.0 mL per site
28 5.60 11.20
29 5.80 11.60 Feline:
30 6.00 12.00 0.2 - 0.3 mL per site
31 6.20 12.40
32 6.40 12.80
33 6.60 13.20 Dilute with sterile water if
34 6.80 13.60
35 7.00 14.00 more volume
36 7.20 14.40 is needed
37 7.40 14.80
38 7.60 15.20
39 7.80 15.60
40 8.00 16.00
41 8.20 16.40
42 8.40 16.80
43 8.60 17.20
44 8.80 17.60
45 9.00 18.00
46 9.20 18.40
47 9.40 18.80
48 9.60 19.20
49 9.80 19.60
50 10.00 20.00
Appendix 186
Buprenorphine 0.3 mg/mL
CANINE FELINE
mLs to administer mLs to administer
Weight Low end
(kg) 0.005 mg/ High end Low end High end Acute pain
0.02 mg/kg 0.01 mg/kg 0.02 mg/kg 0.04 mg/kg
kg
0.5 0.01 0.03 0.02 0.03 0.07
1 0.02 0.07 0.03 0.07 0.13
2 0.03 0.13 0.07 0.13 0.27
3 0.05 0.20 0.10 0.20 0.40
4 0.07 0.27 0.13 0.27 0.53
5 0.08 0.33 0.17 0.33 0.67
6 0.10 0.40 0.20 0.40 0.80
7 0.12 0.47 0.23 0.47 0.93
8 0.13 0.53 0.27 0.53 1.07
9 0.15 0.60 0.30 0.60 1.20
10 0.17 0.67 0.33 0.67 1.33
11 0.18 0.73 0.37 0.73 1.47
12 0.20 0.80 0.40 0.80 1.60
13 0.22 0.87 0.43 0.87 1.73
14 0.23 0.93
15 0.25 1.00
16 0.27 1.07
17 0.28 1.13
18 0.30 1.20
19 0.32 1.27
20 0.33 1.33
21 0.35 1.40
22 0.37 1.47
23 0.38 1.53
24 0.40 1.60
25 0.42 1.67
26 0.43 1.73
27 0.45 1.80
28 0.47 1.87
29 0.48 1.93
30 0.50 2.00
31 0.52 2.07
32 0.53 2.13
33 0.55 2.20
34 0.57 2.27
35 0.58 2.33
36 0.60 2.40
37 0.62 2.47
38 0.63 2.53
39 0.65 2.60
40 0.67 2.67
41 0.68 2.73
42 0.70 2.80
43 0.72 2.87
44 0.73 2.93
45 0.75 3.00
46 0.77 3.07
47 0.78 3.13
48 0.80 3.20
49 0.82 3.27
50 0.83 3.33
187 Book 3
Buprenorphine – long acting 1.8 mg/mL
FELINE
Appendix 188
Butorphanol 10 mg/mL (For analgesia)
CANINE/FELINE
mLs to administer
Weight
(kg) Low end High end
0.2 mg/kg 0.4 mg/kg
0.5 0.01 0.02
1 0.02 0.04
2 0.04 0.08
3 0.06 0.12
4 0.08 0.16
5 0.10 0.20
6 0.12 0.24
7 0.14 0.28
8 0.16 0.32
9 0.18 0.36
10 0.20 0.40
11 0.22 0.44
12 0.24 0.48
13 0.26 0.52
14 0.28 0.56
15 0.30 0.60
16 0.32 0.64
17 0.34 0.68
18 0.36 0.72
19 0.38 0.76
20 0.40 0.80
21 0.42 0.84
22 0.44 0.88
23 0.46 0.92
24 0.48 0.96
25 0.50 1.00
26 0.52 1.04
27 0.54 1.08
28 0.56 1.12
29 0.58 1.16
30 0.60 1.20
31 0.62 1.24
32 0.64 1.28
33 0.66 1.32
34 0.68 1.36
35 0.70 1.40
36 0.72 1.44
37 0.74 1.48
38 0.76 1.52
39 0.78 1.56
40 0.80 1.60
41 0.82 1.64
42 0.84 1.68
43 0.86 1.72
44 0.88 1.76
45 0.90 1.80
46 0.92 1.84
47 0.94 1.88
48 0.96 1.92
49 0.98 1.96
50 1.00 2.00
189 Book 3
Carprofen 50 mg/mL
CANINE
mLs to administer
Weight
(kg) Low end High end
4 mg/kg 4.4 mg/kg
0.5 0.04 0.04
1 0.08 0.09
2 0.16 0.18
3 0.24 0.26
4 0.32 0.35
5 0.40 0.44
6 0.48 0.53
7 0.56 0.62
8 0.64 0.70
9 0.72 0.79
10 0.80 0.88
11 0.88 0.97
12 0.96 1.06
13 1.04 1.14
14 1.12 1.23
15 1.20 1.32
16 1.28 1.41
17 1.36 1.50
18 1.44 1.58
19 1.52 1.67
20 1.60 1.76
21 1.68 1.85
22 1.76 1.94
23 1.84 2.02
24 1.92 2.11
25 2.00 2.20
26 2.08 2.29
27 2.16 2.38
28 2.24 2.46
29 2.32 2.55
30 2.40 2.64
31 2.48 2.73
32 2.56 2.82
33 2.64 2.90
34 2.72 2.99
35 2.80 3.08
36 2.88 3.17
37 2.96 3.26
38 3.04 3.34
39 3.12 3.43
40 3.20 3.52
41 3.28 3.61
42 3.36 3.70
43 3.44 3.78
44 3.52 3.87
45 3.60 3.96
46 3.68 4.05
47 3.76 4.14
48 3.84 4.22
49 3.92 4.31
50 4.00 4.40
Appendix 190
Dexamethasone SP 4 mg/mL
CANINE/FELINE
mLs to administer
Weight
(kg) Low end High end
0.1 mg/kg 0.4 mg/kg
0.5 0.013 0.05
1 0.025 0.10
2 0.050 0.20
3 0.075 0.30
4 0.100 0.40
5 0.125 0.50
6 0.150 0.60
7 0.175 0.70
8 0.200 0.80
9 0.225 0.90
10 0.250 0.10
11 0.275 0.11
12 0.300 0.12
13 0.325 0.13
14 0.350 0.14
15 0.375 0.15
16 0.400 0.16
17 0.425 0.17
18 0.450 0.18
19 0.475 0.19
20 0.500 0.20
21 0.525 0.21
22 0.550 0.22
23 0.575 0.23
24 0.600 0.24
25 0.625 0.25
26 0.650 0.26
27 0.675 0.27
28 0.700 0.28
29 0.725 0.29
30 0.750 0.30
31 0.775 0.31
32 0.800 0.32
33 0.825 0.33
34 0.850 0.34
35 0.875 0.35
36 0.900 0.36
37 0.925 0.37
38 0.950 0.38
39 0.975 0.39
40 1.000 0.40
41 1.025 0.41
42 1.050 0.42
43 1.075 0.43
44 1.100 0.44
45 1.125 0.45
46 1.150 0.46
47 1.175 0.47
48 1.200 0.48
49 1.225 0.49
50 1.250 0.50
191 Book 3
Dexmedetomidine 0.5 mg/mL
CANINE FELINE
mLs to administer mLs to administer
Weight
(kg) Low end High end Low end High end
2 mcg/kg 5 mcg/kg 5 mcg/kg 10 mcg/kg
0.5 0.00 0.01 0.01 0.01
1 0.00 0.01 0.01 0.02
2 0.01 0.02 0.02 0.04
3 0.01 0.03 0.03 0.06
4 0.02 0.04 0.04 0.08
5 0.02 0.05 0.05 0.10
6 0.02 0.06 0.06 0.12
7 0.03 0.07 0.07 0.14
8 0.03 0.08 0.08 0.16
9 0.04 0.09 0.09 0.18
10 0.04 0.10 0.10 0.20
11 0.04 0.11 0.11 0.22
12 0.05 0.12 0.12 0.24
13 0.05 0.13 0.13 0.26
14 0.06 0.14
15 0.06 0.15
16 0.06 0.16
17 0.07 0.17
18 0.07 0.18
19 0.08 0.19
20 0.08 0.20
21 0.08 0.21
22 0.09 0.22 Package insert
23 0.09 0.23
24 0.10 0.24 contains detailed
25 0.10 0.25 dosing instructions
26 0.10 0.26
27 0.11 0.27
28 0.11 0.28 For reversal, administer
29 0.12 0.29 atipamezole IM at
30 0.12 0.30
31 0.12 0.31 equal mL volume to
32 0.13 0.32 dexmedetomidine
33 0.13 0.33
34 0.14 0.34 administered
35 0.14 0.35
36 0.14 0.36
37 0.15 0.37
38 0.15 0.38
39 0.16 0.39
40 0.16 0.40 Usage limited to
41 0.16 0.41 pets with
42 0.17 0.42
43 0.17 0.43 ASA status I - II
44 0.18 0.44
45 0.18 0.45
46 0.18 0.46
47 0.19 0.47
48 0.19 0.48
49 0.20 0.49
50 0.20 0.50
Appendix 192
Diphenhydramine 50 mg/mL
CANINE/FELINE
mLs to administer
Weight
(kg) Low end High end
1mg/kg 2.2 mg/kg
0.5 0.01 0.02
1 0.02 0.04
2 0.04 0.09
3 0.06 0.13
4 0.08 0.18
5 0.10 0.22
6 0.12 0.26
7 0.14 0.31
8 0.16 0.35
9 0.18 0.40
10 0.20 0.44
11 0.22 0.48
12 0.24 0.53
13 0.26 0.57
14 0.28 0.62
15 0.30 0.66
16 0.32 0.7
17 0.34 0.75
18 0.36 0.79
19 0.38 0.84
20 0.40 0.88
21 0.42 0.92
22 0.44 0.97
23 0.46 1.00
24 0.48 1.00
25 0.50
26 0.52
27 0.54
28 0.56
29 0.58
30 0.60
31 0.62
32 0.64
33 0.66
34 0.68
35 0.70 MAXIMUM DOSE
36 0.72 1 ML (50 MG)
37 0.74
38 0.76
39 0.78
40 0.80
41 0.82
42 0.84
43 0.86
44 0.88
45 0.90
46 0.92
47 0.94
48 0.96
49 0.98
50 1.00
193 Book 3
DKT Dexmedetomidine, Ketamine, Butorphanol
FELINE
mLs DKT mL mLs DKT mL
Weight administered atipamezole administered atipamezole
(kg) Compromised Reversal Healthy Reversal
0.035 mL/kg 0.012 mL/kg 0.065 mL/kg 0.021 mL/kg
0.5 0.02 0.01 0.03 0.01
1 0.04 0.01 0.07 0.02
2 0.07 0.02 0.13 0.04
3 0.11 0.04 0.20 0.06
4 0.14 0.05 0.26 0.08
5 0.18 0.06 0.33 0.11
6 0.21 0.07 0.39 0.13
7 0.25 0.08 0.46 0.15
8 0.28 0.10 0.52 0.17
9 0.32 0.11 0.59 0.19
10 0.35 0.12 0.65 0.21
11 0.39 0.13 0.72 0.23
12 0.42 0.14 0.78 0.25
13 0.46 0.16 0.85 0.27
ATIPAMEZOLE REVERSAL:
REPEAT IN 10 MINUTES
IF NEEDED
Appendix 194
Epinephrine 1 mg/mL
CANINE/FELINE
mLs to administer
Weight High end
(kg) Low end
0.2 mg/kg
0.01 mg/kg
(intra-tracheal)
0.5 0.01 0.10
1 0.01 0.20
2 0.02 0.40
3 0.03 0.60
4 0.04 0.80
5 0.05 1.00
6 0.06 1.20
7 0.07 1.40
8 0.08 1.60
9 0.09 1.80
10 0.10 2.00
11 0.11 2.20
12 0.12 2.40
13 0.13 2.60
14 0.14 2.80
15 0.15 3.00
16 0.16 3.20
17 0.17 3.40
18 0.18 3.60
19 0.19 3.80
20 0.20 4.00
21 0.21 4.20
22 0.22 4.40
23 0.23 4.60
24 0.24 4.80
25 0.25 5.00
26 0.26 5.20
27 0.27 5.40
28 0.28 5.60
29 0.29 5.80
30 0.30 6.00
31 0.31 6.20
32 0.32 6.40
33 0.33 6.60
34 0.34 6.80
35 0.35 7.00
36 0.36 7.20
37 0.37 7.40
38 0.38 7.60
39 0.39 7.80
40 0.40 8.00
41 0.41 8.20
42 0.42 8.40
43 0.43 8.60
44 0.44 8.80
45 0.45 9.00
46 0.46 9.20
47 0.47 9.40
48 0.48 9.60
49 0.49 9.80
50 0.50 10.00
195 Book 3
Fentanyl 0.05 mg/mL
CANINE/FELINE
mLs to administer
Weight
(kg) Low end High end
3 mcg/kg 5 mcg/kg
0.5 0.03 0.05
1 0.06 0.10
2 0.12 0.20
3 0.18 0.30
4 0.24 0.40
5 0.30 0.50
6 0.36 0.60
7 0.42 0.70
8 0.48 0.80
9 0.54 0.90
10 0.60 1.00
11 0.66 1.10
12 0.72 1.20
13 0.78 1.30
14 0.84 1.40
15 0.90 1.50
16 0.96 1.60
17 1.02 1.70
18 1.08 1.80
19 1.14 1.90
20 1.20 2.00
21 1.26 2.10
22 1.32 2.20
23 1.38 2.30
24 1.44 2.40
25 1.50 2.50
26 1.56 2.60
27 1.62 2.70
28 1.68 2.80
29 1.74 2.90
30 1.80 3.00
31 1.86 3.10
32 1.92 3.20
33 1.98 3.30
34 2.04 3.40
35 2.10 3.50
36 2.16 3.60
37 2.22 3.70
38 2.28 3.80
39 2.34 3.90
40 2.40 4.00
41 2.46 4.10
42 2.52 4.20
43 2.58 4.30
44 2.64 4.40
45 2.70 4.50
46 2.76 4.60
47 2.82 4.70
48 2.88 4.80
49 2.94 4.90
50 3.00 5.00
Appendix 196
Flumazenil 0.1 mg/mL
CANINE/FELINE
mLs to administer
Weight
(kg) 0.01 mg/kg
Repeat every hour if needed
0.5 0.05
1 0.1
2 0.2
3 0.3
4 0.4
5 0.5
6 0.6
7 0.7
8 0.8
9 0.9
10 1.0
11 1.1
12 1.2
13 1.3
14 1.4
15 1.5
16 1.6
17 1.7
18 1.8
19 1.9
20 2.0
21 2.1
22 2.2
23 2.3
24 2.4
25 2.5
26 2.6
27 2.7
28 2.8
29 2.9
30 3.0
31 3.1
32 3.2
33 3.3
34 3.4
35 3.5
36 3.6
37 3.7
38 3.8
39 3.9
40 4.0
41 4.1
42 4.2
43 4.3
44 4.4
45 4.5
46 4.6
47 4.7
48 4.8
49 4.9
50 5.0
197 Book 3
Glycopyrrolate 0.2 mg/mL
CANINE/FELINE
mLs to administer
Weight
(kg) Low end High end
0.005 mg/kg 0.01 mg/kg
0.5 0.01 0.03
1 0.03 0.05
2 0.05 0.10
3 0.08 0.15
4 0.10 0.20
5 0.13 0.25
6 0.15 0.30
7 0.18 0.35
8 0.20 0.40
9 0.23 0.45
10 0.25 0.50
11 0.28 0.55
12 0.30 0.60
13 0.33 0.65
14 0.35 0.70
15 0.38 0.75
16 0.40 0.80
17 0.43 0.85
18 0.45 0.90
19 0.48 0.95
20 0.50 1.00
21 0.53 1.05
22 0.55 1.10
23 0.58 1.15
24 0.60 1.20
25 0.63 1.25
26 0.65 1.30
27 0.68 1.35
28 0.70 1.40
29 0.73 1.45
30 0.75 1.50
31 0.78 1.55
32 0.80 1.60
33 0.83 1.65
34 0.85 1.70
35 0.88 1.75
36 0.90 1.80
37 0.93 1.85
38 0.95 1.90
39 0.98 1.95
40 1.00 2.00
41 1.03 2.05
42 1.05 2.10
43 1.08 2.15
44 1.10 2.20
45 1.13 2.25
46 1.15 2.30
47 1.18 2.35
48 1.20 2.40
49 1.23 2.45
50 1.25 2.50
Appendix 198
Hydromorphone 2 mg/mL
CANINE FELINE
mLs to administer mLs to administer
Weight
(kg) Low end High end Low end High end
0.05 mg/kg 0.2 mg/kg 0.05 mg/kg 0.1 mg/kg
0.5 0.01 0.05 0.01 0.03
1 0.03 0.10 0.03 0.05
2 0.05 0.20 0.05 0.10
3 0.08 0.30 0.08 0.15
4 0.10 0.40 0.10 0.20
5 0.13 0.50 0.13 0.25
6 0.15 0.60 0.15 0.30
7 0.18 0.70 0.18 0.35
8 0.20 0.80 0.20 0.40
9 0.23 0.90 0.23 0.45
10 0.25 1.00 0.25 0.50
11 0.28 1.10 0.28 0.55
12 0.30 1.20 0.30 0.60
13 0.33 1.30 0.33 0.65
14 0.35 1.40
15 0.38 1.50
16 0.40 1.60
17 0.43 1.70
18 0.45 1.80
19 0.48 1.90
20 0.50 2.00
21 0.53 2.10
22 0.55 2.20
23 0.58 2.30
24 0.60 2.40
25 0.63 2.50
26 0.65 2.60
27 0.68 2.70
28 0.70 2.80
29 0.73 2.90
30 0.75 3.00
31 0.78 3.10
32 0.80 3.20
33 0.83 3.30
34 0.85 3.40
35 0.88 3.50
36 0.90 3.60
37 0.93 3.70
38 0.95 3.80
39 0.98 3.90
40 1.00 4.00
41 1.03 4.10
42 1.05 4.20
43 1.08 4.30
44 1.10 4.40
45 1.13 4.50
46 1.15 4.60
47 1.18 4.70
48 1.20 4.80
49 1.23 4.90
50 1.25 5.00
199 Book 3
100 mg/mL
Ketamine (For stressed/fractious canines)
CANINE
Appendix 200
20 mg/mL
Lidocaine Bolus (For cardiac arrhythmias)
CANINE FELINE
mLs to administer mLs to administer
Weight
(kg) Low end High end High end
2 mg/kg 4 mg/kg 0.2 mg/kg
0.5 0.05 0.10 0.01
1 0.10 0.20 0.01
2 0.20 0.40 0.02
3 0.30 0.60 0.03
4 0.40 0.80 0.04
5 0.50 1.00 0.05
6 0.60 1.20 0.06
7 0.70 1.40 0.07
8 0.80 1.60 0.08
9 0.90 1.80 0.09
10 1.00 2.00 0.10
11 1.10 2.20 0.11
12 1.20 2.40 0.12
13 1.30 2.60 0.13
14 1.40 2.80
15 1.50 3.00
16 1.60 3.20
17 1.70 3.40
18 1.80 3.60
19 1.90 3.80
20 2.00 4.00
21 2.10 4.20
22 2.20 4.40 MAXIMUM
23 2.30 4.60
24 2.40 4.80 DOSAGE
25 2.50 5.00
26 2.60 5.20 Canine:
27 2.70 5.40 8 mg/kg
28 2.80 5.60
29 2.90 5.80 Feline:
30 3.00 6.00
31 3.10 6.20 1 mg/kg
32 3.20 6.40
33 3.30 6.60 Administer
34 3.40 6.80
35 3.50 7.00 slowly over
36 3.60 7.20 1 - 2 minutes
37 3.70 7.40
38 3.80 7.60
39 3.90 7.80
40 4.00 8.00
41 4.10 8.20
42 4.20 8.40
43 4.30 8.60
44 4.40 8.80
45 4.50 9.00
46 4.60 9.20
47 4.70 9.40
48 4.80 9.60
49 4.90 9.80
50 5.00 10.00
201 Book 3
Lidocaine 20 mg/mL (For local anesthesia)
CANINE FELINE
mLs to administer mLs to administer
Weight
(kg) Low end High end Low end High end
1 mg/kg 4 mg/kg 1 mg/kg 2 mg/kg
0.5 0.03 0.10 0.03 0.05
1 0.05 0.20 0.05 0.10
2 0.10 0.40 0.10 0.20
3 0.15 0.60 0.15 0.30
4 0.20 0.80 0.20 0.40
5 0.25 1.00 0.25 0.50
6 0.30 1.20 0.30 0.60
7 0.35 1.40 0.35 0.70
8 0.40 1.60 0.40 0.80
9 0.45 1.80 0.45 0.90
10 0.50 2.00 0.50 1.00
11 0.55 2.20 0.55 1.10
12 0.60 2.40 0.60 1.20
13 0.65 2.60 0.65 1.30
14 0.70 2.80
15 0.75 3.00
16 0.80 3.20
17 0.85 3.40
18 0.90 3.60 MAXIMUM DOSAGE
19 0.95 3.80
20 1.00 4.00 Canine:
21 1.05 4.20
22 1.10 4.40 10 mg/kg
23 1.15 4.60
24 1.20 4.80 Feline:
25 1.25 5.00
26 1.30 5.20 5 mg/kg
27 1.35 5.40
28 1.40 5.60
29 1.45 5.80
30 1.50 6.00
31 1.55 6.20
32 1.60 6.40 LOCAL INJECTION
33 1.65 6.60 GUIDELINES
34 1.70 6.80
35 1.75 7.00 Canine:
36 1.80 7.20
37 1.85 7.40 0.5 - 1.0 mL per site
38 1.90 7.60
39 1.95 7.80 Feline:
40 2.00 8.00
41 2.05 8.20 0.2 - 0.3 mL per site
42 2.10 8.40
43 2.15 8.60 Dilute with sterile
44 2.20 8.80 water if more
45 2.25 9.00
46 2.30 9.20 volume is needed
47 2.35 9.40
48 2.40 9.60
49 2.45 9.80
50 2.50 10.00
Appendix 202
Meloxicam 5 mg/mL
CANINE FELINE
203 Book 3
Methadone 10mg/mL
CANINE/FELINE
mLs to administer
Weight
(kg) Low end High end
(0.1 mg/kg) (0.5 mg/kg)
0.5 0.005 0.025
1 0.01 0.05
2 0.02 0.10
3 0.03 0.15
4 0.04 0.20
5 0.05 0.25
6 0.06 0.30
7 0.07 0.35
8 0.08 0.40
9 0.09 0.45
10 0.10 0.50
11 0.11 0.55
12 0.12 0.60
13 0.13 0.65
14 0.14 0.70
15 0.15 0.75
16 0.16 0.80
17 0.17 0.85
18 0.18 0.90
19 0.19 0.95
20 0.20 1.00
21 0.21 1.05
22 0.22 1.10
23 0.23 1.15
24 0.24 1.20
25 0.25 1.25
26 0.26 1.30
27 0.27 1.35
28 0.28 1.40
29 0.29 1.45
30 0.30 1.50
31 0.31 1.55
32 0.32 1.60
33 0.33 1.65
34 0.34 1.70
35 0.35 1.75
36 0.36 1.80
37 0.37 1.85
38 0.38 1.90
39 0.39 1.95
40 0.40 2.00
41 0.41 2.05
42 0.42 2.10
43 0.43 2.15
44 0.44 2.20
45 0.45 2.25
46 0.46 2.30
47 0.47 2.35
48 0.48 2.40
49 0.49 2.45
50 0.50 2.50
Appendix 204
Midazolam 1 mg/mL
CANINE/FELINE
mLs to administer
Weight
(kg) Low end High end
0.1 mg/kg 0.3 mg/kg
0.5 0.05 0.15
1 0.10 0.30
2 0.20 0.60
3 0.30 0.90
4 0.40 1.20
5 0.50 1.50
6 0.60 1.80
7 0.70 2.10
8 0.80 2.40
9 0.90 2.70
10 1.00 3.00
11 1.10 3.30
12 1.20 3.60
13 1.30 3.90
14 1.40 4.20
15 1.50 4.50
16 1.60 4.80
17 1.70 5.10
18 1.80 5.40
19 1.90 5.70
20 2.00 6.00
21 2.10 6.30
22 2.20 6.60
23 2.30 6.90
24 2.40 7.20
25 2.50 7.50
26 2.60 7.80
27 2.70 8.10
28 2.80 8.40
29 2.90 8.70
30 3.00 9.00
31 3.10 9.30
32 3.20 9.60
33 3.30 9.90
34 3.40 10.20
35 3.50 10.50
36 3.60 10.80
37 3.70 11.10
38 3.80 11.40
39 3.90 11.70
40 4.00 12.00
41 4.10 12.30
42 4.20 12.60
43 4.30 12.90
44 4.40 13.20
45 4.50 13.50
46 4.60 13.80
47 4.70 14.10
48 4.80 14.40
49 4.90 14.70
50 5.00 15.00
205 Book 3
Midazolam 5 mg/mL
CANINE/FELINE
mLs to administer
Weight
(kg) Low end High end
0.1 mg/kg 0.3 mg/kg
0.5 0.01 0.03
1 0.02 0.06
2 0.04 0.12
3 0.06 0.18
4 0.08 0.24
5 0.10 0.30
6 0.12 0.36
7 0.14 0.42
8 0.16 0.48
9 0.18 0.54
10 0.20 0.60
11 0.22 0.66
12 0.24 0.72
13 0.26 0.78
14 0.28 0.84
15 0.30 0.90
16 0.32 0.96
17 0.34 1.02
18 0.36 1.08
19 0.38 1.14
20 0.40 1.20
21 0.42 1.26
22 0.44 1.32
23 0.46 1.38
24 0.48 1.44
25 0.50 1.50
26 0.52 1.56
27 0.54 1.62
28 0.56 1.68
29 0.58 1.74
30 0.60 1.80
31 0.62 1.86
32 0.64 1.92
33 0.66 1.98
34 0.68 2.04
35 0.70 2.10
36 0.72 2.16
37 0.74 2.22
38 0.76 2.28
39 0.78 2.34
40 0.80 2.40
41 0.82 2.46
42 0.84 2.52
43 0.86 2.58
44 0.88 2.64
45 0.90 2.70
46 0.92 2.76
47 0.94 2.82
48 0.96 2.88
49 0.98 2.94
50 1.00 3.00
Appendix 206
Naloxone 0.4 mg/mL
CANINE/FELINE
mLs to administer
Weight
(kg) 0.04 mg/kg
Repeat every hour if needed
0.5 0.05
1 0.1
2 0.2
3 0.3
4 0.4
5 0.5
6 0.6
7 0.7
8 0.8
9 0.9
10 1.0
11 1.1
12 1.2
13 1.3
14 1.4
15 1.5
16 1.6
17 1.7
18 1.8
19 1.9
20 2.0
21 2.1
22 2.2
23 2.3
24 2.4
25 2.5
26 2.6
27 2.7
28 2.8
29 2.9
30 3.0
31 3.1
32 3.2
33 3.3
34 3.4
35 3.5
36 3.6
37 3.7
38 3.8
39 3.9
40 4.0
41 4.1
42 4.2
43 4.3
44 4.4
45 4.5
46 4.6
47 4.7
48 4.8
49 4.9
50 5.0
207 Book 3
Propofol 10 mg/mL
CANINE/FELINE
mLs to administer
Weight
(kg) Low end High end
1 mg/kg 8 mg/kg
0.5 0.05 0.40
1 0.10 0.80
2 0.20 1.60
3 0.30 2.40
4 0.40 3.20
5 0.50 4.00
6 0.60 4.80
7 0.70 5.60
8 0.80 6.40
9 0.90 7.20
10 1.00 8.00
11 1.10 8.80
12 1.20 9.60
13 1.30 10.40
14 1.40 11.20
15 1.50 12.00
16 1.60 12.80 SEE DOSING
17 1.70 13.60
18 1.80 14.40 INSTRUCTIONS
19 1.90 15.20
20 2.00 16.00 IN TEXT
21 2.10 16.80 Administer only
22 2.20 17.60
23 2.30 18.40 to effect
24 2.40 19.20
25 2.50 20.00
26 2.60 20.80
27 2.70 21.60
28 2.80 22.40
29 2.90 23.20
30 3.00 24.00
31 3.10 24.80
32 3.20 25.60
33 3.30 26.40
34 3.40 27.20
35 3.50 28.00
36 3.60 28.80
37 3.70 29.60
38 3.80 30.40
39 3.90 31.20
40 4.00 32.00
41 4.10 32.80
42 4.20 33.60
43 4.30 34.40
44 4.40 35.20
45 4.50 36.00
46 4.60 36.80
47 4.70 37.60
48 4.80 38.40
49 4.90 39.20
50 5.00 40.00
Appendix 208
Robenacoxib 20 mg/mL
FELINE
209 Book 3
Tiletamine/Zolazepan 100 mg/mL
CANINE/FELINE
Appendix 210
References and suggested reading for Appendix:
1. Dodelet-Devillers et al. Assessment of stability of ketamine-xylazine
preparations with or without acepromazine using high performance liquid
chromatography-mass spectrometry. Can J Vet Res. Jan 2016;80(1):
86-89.
2. Taylor BJ, Orr SA, Chapman JL, et al. Beyond-use dating of
extemporaneously compounded ketamine, acepromazine,and xylazine:
safety, stability, and efficacy over time. J Am Assoc Lab Anim Sci. Nov
2009:48(6)718-726.
3. Kwiatkowski JL, Johnson CE, Wagner DS. Extended stability of intravenous
acetaminophen in syringes and opened vials. Am J Health Syst Pharm. 2012
Nov 2012;69(22):1999-2001.
4. U.S. Pharmacopeial Convention (USP). General Chapter 797. www.usp.org/.
Accessed February 15, 2017.
5. Hofmeister EH, Egger CM. Transdermal fentanyl patches in small animals. J
Am Anim Hosp Assoc. 2004;40(6):468-478.
211 Book 3